

that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary, scPharmaceuticals Securities Corporation. Certain information and disclosures normally included in financial statements in accordance with U.S. GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 13, 2024. The Company has determined that it operates in one segment. The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2023 and 2024 and condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2024 are unaudited. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with that used to prepare the Company's audited annual financial statements and include, in the opinion of management, adjustments, consisting of normal recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full year ending December 31, 2024. As of September 30, 2024, the Company had an accumulated deficit of approximately \$347.6 million. Management expects to continue to incur operating losses for the foreseeable future. The Company has financed its operations to date from proceeds from the sale of common stock, preferred stock and the incurrence of debt. As of September 30, 2024, the Company had cash and cash equivalents of \$91.5 million. On October 13, 2022, the Company entered into a Credit Agreement and Guaranty (the "Oaktree Agreement") with, among others, the lenders from time to time party thereto and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the lenders (Note 9). On August 9, 2024 (the "Closing Date"), the Company entered into a Credit Agreement and Guaranty (the "Credit Agreement") with the guarantors from time to time party thereto, the lenders from time to time party thereto (the "Lenders"), and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lenders (in such capacity, the "Agent") (Note 9). On the Closing Date, the Company also entered into a Revenue Participation Right Purchase and Sale Agreement (the "Revenue Purchase and Sale Agreement") with Perceptive Credit Holdings IV, LP (the "Purchaser") (Note 9). The Company used the proceeds of the Credit Agreement and the Revenue Purchase and Sale Agreement to, on the Closing Date, prepay all outstanding obligations under the Oaktree Agreement, including the payment of fees and expenses associated with the Oaktree Agreement. In addition, on August 13, 2024, the Company completed an underwritten public offering of shares of its common stock (and, in lieu of such shares of common stock to selected investors, pre-funded warrants to purchase shares of its common stock) with net proceeds of \$53.5 million (Note 10). As the Company's existing cash and cash equivalents will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. Additionally, the Company expects to have access to funds pursuant to an at-the-market offering program with Cowen and Company, LLC (Note 10), or could otherwise seek \$9 additional funding through a combination of public or private equity offerings if it believes additional resources are needed. Additional financing may not be available on a timely basis on terms acceptable to the Company, or at all. 2. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consists of bank deposits and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company's cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Accounts Receivable Accounts receivable are recorded net of any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material credit loss allowance for uncollectible trade receivables. Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold a minimum rating, thereby reducing credit risk exposure. Customer and Supplier Concentration The Company has a limited number of specialty pharmacy customers and distributors. As of December 31, 2023 and September 30, 2024, three customers represented 99% and two customers represented 98% of accounts receivable, respectively. For the three and nine months ended September 30, 2024, two customers represented 98% and three customers represented 99% of revenue, respectively. For the three and nine months ended September 30, 2023, two customers represented 92% and one customer represented 88% of revenue, respectively. The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024, one supplier represented 47% and three suppliers represented 49% of accounts payable, respectively. For the three and nine months ended September 30, 2024, two suppliers represented 45% and 49% of purchases, respectively. For the three and nine months ended September 30, 2023, one supplier represented 29% and two suppliers represented 40% of purchases, respectively. The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations. Investments The Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any 9 10 adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is "other than temporary," including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss. Inventory Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets. ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Debt Issuance Costs Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023. Fair Value Option As permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments ("ASC 825"), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred. The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States. 10 11 Product Net Sales FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies ("Ps") and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either as a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Sales Discounts: Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Company's sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized. Rebates: Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Company's estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Co-Payment Assistance: The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Company's estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period. Product Returns: Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. Research and Development Costs Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead. Income Taxes The Company accounts for income taxes in accordance with the FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized. 11 12 The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is "more likely than not" to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals. As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Company's fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years. 3. Net Loss per Share Net Loss per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data):

| | Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2023 |
|---|---------------------------------------|--------------------------------------|---------------------------------------|--------------------------------------|
| Net loss | \$ (15,634) | \$ (35,105) | \$ (40,998) | \$ (66,303) |
| Weighted-average shares used in computing net loss per share | 38,760,895 | 46,558,474 | 38,421,676 | 41,516,917 |
| Net loss per share, basic and diluted | \$ (0.41) | \$ (0.75) | \$ (1.07) | \$ (1.60) |
| Basic and diluted weighted average shares of common stock outstanding for the three and nine months ended September 30, 2024 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is \$0.001 per share. The Company's potentially dilutive securities, which include unexercised stock options outstanding, unexercised warrants and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. | 38,760,895 | 46,558,474 | 38,421,676 | 41,516,917 |
| Stock options to purchase common stock | 4,722,050 | 5,445,475 | 4,722,050 | 5,445,475 |

incur substantial additional expenditures in the near future to support our ongoing activities and commercialization of FUROSCIX. We expect our costs and expenses to increase in the future as we continue U.S. commercialization of FUROSCIX, including the expansion of our direct sales force, and as we continue to make substantial expenditures on research and 29 30 development, including to increase our manufacturing capacity and for conducting clinical trials of our product candidates. Additionally, we continue to incur additional costs as a result of operating as a public company. We plan to continue to fund our operations through cash and cash equivalents on hand. Additionally, we expect to have access to funds pursuant to our at-the-market offering program with Cowen and Company, LLC, or we could otherwise seek additional funding through a combination of public or private equity offerings if we believe additional resources are needed. Our future capital requirements will depend on many factors, including without limitation: the costs and expenses of expanding our U.S. sales and marketing infrastructure; the costs and expenses related to the manufacturing of FUROSCIX and our agreements with third-party manufacturers; the degree of success we experience in commercializing FUROSCIX; the revenue generated by sales of FUROSCIX and of other product candidates that may be approved; the pricing and reimbursement of FUROSCIX and of other product candidates that may be approved; the costs, timing and outcomes of clinical trials and regulatory reviews associated with our product candidates; the emergence of competing or complementary technological developments; the extent to which FUROSCIX is adopted by the healthcare community; the number and types of future products we develop and commercialize; the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and the extent and scope of our general and administrative expenses. A Additional financing may not be available on a timely basis on terms acceptable to us, or at all. We may raise funds in equity, royalty-based or debt financings or enter into additional credit facilities in order to access funds for our capital needs. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution in their percentage ownership of our Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we raise additional funds through royalty-based financing arrangements, we will likely agree to relinquish rights to potentially valuable future revenue streams and may agree to covenants that restrict our operations or strategic flexibility. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment or expansion of sales and marketing capabilities or other activities necessary to commercialize our products. For example, the trading prices for our and other biopharmaceutical companies' securities have been highly volatile as a result of macroeconomic conditions and developments in our industry. As a result, we may face difficulties raising capital through sales of our securities and any such sales may be on unfavorable terms. Additionally, our ability to raise capital may be further impacted by global macroeconomic conditions including, for example, as a result of international political conflict and/or instability, including due to war or terrorism, supply chain issues and rising inflation and interest rates. CASH FLOWS The following table summarizes our sources and uses of cash for each of the periods presented: A A Nine Months Ended September 30, A (in thousands) A A 2023 A A 2024 A Net cash (used in) provided by: A A A A Operating activities A \$ (44,086) A \$ (55,352) A Investing activities A (6,498) A 29,311 A Financing activities A 14,383 A A 70,711 A Net (decrease) increase in cash and cash equivalents A \$ (36,201) A \$ 44,670 A A 30 31 Net Cash Used in Operating Activities During the nine months ended September 30, 2024, net cash used in operating activities was \$55.4 million, consisting primarily of a net loss of \$66.3 million and an increase in net operating assets of \$13.3 million. This was offset by non-cash charges of \$24.2 million. The increase in net operating assets is related to accounts receivable and inventory to support the ongoing commercial operations of FUROSCIX. The non-cash charges primarily consisted of depreciation, amortization related to our right-of-use leased assets, stock-based compensation expense, non-cash interest expense related to amortization of debt discount associated with the Oaktree Agreement, the fair value adjustments to the derivative liability, term loan and revenue purchase and sale liability, debt issuance costs, and the loss on the extinguishment of the Oaktree Agreement and accretion of premium on investments. During the nine months ended September 30, 2023, net cash used in operating activities was \$44.1 million, consisting primarily of a net loss of \$41.0 million and an increase in net operating assets of \$5.8 million. This was offset by non-cash charges of \$2.7 million. The increase in net operating assets is related to accounts receivable and inventory to support the launch of FUROSCIX. The non-cash charges primarily consisted of depreciation, amortization related to our right-of-use leased assets, stock-based compensation expense, non-cash interest expense related to amortization of debt discount associated with the Oaktree Agreement, the fair value adjustment to the derivative liability and accretion of premium on investments. Net Cash (Used in) Provided by Investing Activities During the nine months ended September 30, 2024, net cash provided by investing activities was \$29.3 million, consisting of maturities of short-term investments. During the nine months ended September 30, 2023, net cash used in investing activities was \$6.5 million, consisting primarily of purchases of short-term investments, net of maturities. Net Cash Provided by Financing Activities During the nine months ended September 30, 2024, net cash provided by financing activities was \$70.7 million due to proceeds from the Perceptive Financing, proceeds from the sale of common stock, purchases pursuant to our 2017 Employee Stock Purchase Plan and stock option exercises, offset by the payoff of the Oaktree Agreement, and related fees, and amounts paid to settle restricted stock unit tax withholding obligations. During the nine months ended September 30, 2023, net cash provided by financing activities was \$14.4 million, consisting of proceeds from the 2021 ATM Agreement, purchases pursuant to our 2017 Employee Stock Purchase Plan and stock option exercises. CRITICAL ACCOUNTING POLICIES AND ESTIMATES Management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. Our critical accounting policies are more fully described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report. There have been no material changes to that information disclosed in our Annual Report during the nine months ended September 30, 2024. A Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are exposed to market risks related to changes in foreign currency exchange rates and interest rates. We contract with vendors in foreign countries. As such, we have exposure to adverse changes in exchange rates of foreign currencies, principally the Swiss franc and Euro, associated with our foreign transactions. We believe this exposure to be immaterial. We currently do not hedge against this exposure to fluctuations in exchange rates. A Our exposure to market risk also relates to interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. We have elected the fair value option for certain liabilities. The fair value of the liabilities related to the Credit Agreement and the Revenue Purchase and Sale Agreement will increase as market interest rates decrease. In addition, the fair 31 32 value of the liabilities may fluctuate based upon changes in the Company's credit rating. Changes in the interest rate environment and the credit rating of the Company could have an effect on our future earnings. A We do not believe that inflation has had a material effect on our business. However, if our costs, in particular costs related to manufacture and supply, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. Item 4. Controls and Procedures. Limitations on Effectiveness of Controls and Procedures In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. A Evaluation of Disclosure Controls and Procedures Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation of our disclosure controls and procedures as of September 30, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were not effective at a reasonable assurance level due to the continued material weakness in our internal control over financial reporting as described below and in Item 9A, Controls and Procedures, in our Annual Report which was filed on March 13, 2024. A In light of the identified material weakness, we performed additional analysis and other procedures around the review of the calculation performed by our third-party valuation specialist. A Previously Reported Material Weakness in Internal Control over Financial Reporting As previously disclosed in Item 9A, Controls and Procedures, on Form 10-K filed March 13, 2024, as of and for the year ended December 31, 2023, we identified a deficiency resulting in a material weakness further described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Beginning with the preparation of our financial statements in our Annual Report on Form 10-K, management identified a material weakness related to the controls, processes and procedures over the fair value accounting associated with its financial liabilities measured at fair value. Please see Note 9, Debt, to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of the financial liabilities. Specifically, the calculations performed by our third-party valuation specialist during the fourth quarter of fiscal 2023 and third quarter of fiscal 2024 as it relates to fair value accounting for the liabilities included errors resulting in an overstatement in the fair values. We made adjustments necessary to properly reflect the fair value of the instruments in the financial statements, as applicable, included in our Annual Report and in this Quarterly Report. There were no changes to previously released financial results as a result of this material weakness. A Remediation Plan Management is actively working to remediate the identified material weakness and is committed to remediating the material weakness in a timely manner. Our remediation process is ongoing and includes the following steps, but is not limited to the following: (a) additional quality control processes implemented by our third-party valuation specialist, (b) detailed discussions around changes in assumptions used in the valuation and their effect on the valuation, and (c) more thorough review of sample iterations used in determining the fair value of the derivative. While the audit committee of our board of directors and senior management are closely monitoring the remediation efforts, until the remediation efforts discussed in this section, including any additional remediation efforts that our senior management identifies as necessary, are complete, tested and determined effective, we will not be able to conclude that the material weakness has been remediated. The material weakness will not be considered remediated until the controls are in place for a period of time and management concludes based on its evaluation that these controls are properly designed and operating effectively. A 32 33 Changes in Internal Control over Financial Reporting Other than the material weakness described above, there were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A 33 34 PART II "OTHER INFORMATION" Item 1. Legal Proceedings From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. Information regarding risk factors appears in Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 (the "Annual Report"), which was filed with the SEC on March 13, 2024. There have been no material changes from the risk factors previously disclosed in our Annual Report. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. A None. (b) Material changes to the procedures by which security holders may recommend nominees to the board of directors. None. (c) Insider Trading Arrangements and Policies. A During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits A 34 35 EXHIBIT INDEX Exhibit Number Description A A 3.1 A Second Amended and Restated Certificate of Incorporation of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on November 21, 2017). A A A 3.2 A Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on November 21, 2017). A A A 3.3 A Amendment No. 1 to the Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on June 10, 2020). A A A 3.4 A Amendment No. 2 to the Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on March 12, 2021). A A A 4.1 A Form of Warrant, dated October 13, 2022, issued by scPharmaceuticals Inc. to certain lenders, together with a schedule of warrant holders (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on October 14, 2022). A A A 4.2 A Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on November 23, 2022). A A A 4.3 A Warrant, dated August 9, 2024, issued by scPharmaceuticals, Inc. to Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 4.4 A Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on August 13, 2024). A A A 10.1 A Credit Agreement and Guaranty, by and among the Company, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lender, dated August 9, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 10.2 A Revenue Purchase and Sale Agreement, dated August 9, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A A 101* Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q. A A A 104* A Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101*). A * Filed herewith. ** Furnished herewith. A 35 36 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A A SCPHARMACEUTICALS INC. A A A Date: November 13, 2024 A By: /s/ Rachael Nokes A A A Rachael Nokes A A A Chief Financial Officer (Principal Financial Officer) A 36 EX-31.1 2 scph-ex31.1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION I, John H. Tucker, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of scPharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and

presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 13, 2024 /s/ John H. Tucker John H. Tucker President and Chief Executive Officer (Principal Executive Officer) A A EX-31.2 4 sph-ex31.2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION I, Rachael Nokes, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of scPharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 13, 2024 /s/ Rachael Nokes Rachael Nokes Chief Financial Officer (Principal Financial Officer) A A EX-32.1 4 sph-ex32.1.htm EX-32.1 EX-32.1 A Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report on Form 10-Q of scPharmaceuticals Inc. (the "Company") for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John H. Tucker, President and Chief Executive Officer (Principal Executive Officer), hereby certify, pursuant to 18 U.S.C. A1350, as adopted pursuant to A906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: A 1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: November 13, 2024 /s/ John H. Tucker John H. Tucker A A President and Chief Executive Officer A A (Principal Executive Officer) A A EX-32.2 5 sph-ex32.2.htm EX-32.2 EX-32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report on Form 10-Q of scPharmaceuticals Inc. (the "Company") for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Rachael Nokes, Chief Financial Officer (Principal Financial Officer), hereby certify, pursuant to 18 U.S.C. A1350, as adopted pursuant to A906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: A 1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: November 13, 2024 /s/ Rachael Nokes Rachael Nokes A A Chief Financial Officer A A (Principal Financial Officer) A EX-101.SCH 6 sph-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Financial Liabilities link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Financial Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Net Loss per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Investments - Summary of Available-for-Sale Classified Investments (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Inventory - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Property and Equipment - Schedule of Purchased Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Financial Liabilities - Schedule of Fair Value of Debt Balance (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Financial Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value of Options Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-Based Compensation - Summary of Information about Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Commitments and Contingencies - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Commitments and Contingencies - Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink (Discount) premium (Discount) premium Debt Instrument, Unamortized Discount (Premium), Net Debt Instrument, Unamortized Discount (Premium), Net, Total Statement [Line Items] Statement [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] AGGREGATE INTRINSIC VALUE Liabilities, Fair Value Disclosure [Abstract] Liabilities: Term Loan Term Loan [Member] Term loan, Debt Instrument [Axis] Debt Instrument Increase (Decrease) in Accounts Receivable Accounts receivable Plan Name [Domain] Plan Name Entity Address, Postal Zip Code Entity Address, Postal Zip Code Funded Immediately Borrowings One [Member] Borrowings one, Office Equipment [Member] Office Equipment Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Measurement input Derivative Liability, Measurement Input Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense Long term additional debt discount exit fee, Long Term Additional Debt Discount Exit Fee Long term additional debt discount exit fee Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average exercise prices, vested and exercisable ending balance Lessee operating lease liability payments due after year four, Lessee Operating Lease Liability Payments Due After Year Four Thereafter Shares, Outstanding Ending Balance, Shares Beginning Balance, Shares Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Long-Term Debt, Type [Domain] Long-term Debt, Type Disclosure of information about stockholders equity note, Stockholders Equity Note [Table] Stockholders Equity Note [Table] Long-Term Debt, Current Maturities Term loan, short-term Less: current portion Long-term Debt, Current Maturities, Total December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Stock Options To Purchase Common Stock Member Stock options to purchase common stock, Stock Options To Purchase Common Stock [Member] Stock Options to Purchase Common Stock Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Vesting of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Schedule of Changes in Fair Value of Level 3 Derivative Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Unvested Restricted Stock Units Member Unvested restricted stock units, Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Information [Table] Concentration Risk Benchmark [Axis] Cowen and Company, LLC, Cowen And Company L L C [Member] Cowen Equity [Text Block] Stockholders' Equity Warrants to purchase common stock, Warrants to purchase common stock [Member] Warrants to Purchase Common Stock Sale of Stock [Domain] Sale of Stock Par value of the term loan Total minimum principal payments Face value Loan and security agreement, amount Inventory, Policy [Policy Text Block] Inventory Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Entity Central Index Key Entity Central Index Key Warrant [Member] Warrants Cash paid for amounts included in measurement of lease liabilities, Cash Paid For Amounts Included In Measurement Of Lease Liabilities Cash paid for amounts included in the measurement of lease liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of shares forfeited Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Compensating Balance, Amount Unrestricted cash Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Business Description and Basis of Presentation [Text Block] Description of Business and Basis of Presentation Income Statement [Abstract] Line items represent stockholders equity note, Stockholders Equity Note [Line Items] Stockholders Equity Note [Line Items] Entity Address, State or Province Entity Address, State or Province Total fair value of the term loan Fair value of debt Debt Instrument, Fair Value Disclosure Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock through employee stock purchase plan Unrealized Gain (Loss) on Investments [Table Text Block] Summary of Available-for-Sale Classified Investments Payments to Acquire Short-Term Investments Purchases of short-term investments Purchases of short-term investments Concentration Risk Type [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Customer [Axis] Customer Concentration Risk Transfer of issuance costs from other noncurrent assets to equity, Transfer of issuance costs from other noncurrent assets to equity Transfer of issuance costs from other noncurrent assets to equity Lease, Cost [Abstract] Lease cost: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, vested and exercisable ending balance Investments Classified by Contractual Maturity Date [Table Text Block] Summary of Amortized Cost and Fair Value of Available-for-Sale Investments by Contract Maturity Inventory, Raw Materials, Gross Raw materials Cover [Abstract] Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share - basic Net loss per share, basic 2024 public offering, Two Thousand Twenty Four Public Offering

[Member] 2024 Public Offering Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accumulated Unrealized Gains Operating Expenses [Abstract] Operating expenses: Other lease information. Other Lease Information [Abstract] Other information Aggregate offering price. Aggregate Offering Price Aggregate offering price Investments, Debt and Equity Securities [Abstract] Share-Based Payment Arrangement, Expense Total stock-based compensation expense Long-Term Debt Total RSUs outstanding RSUs outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Plan Name [Axis] Plan Name Deposits and other assets current. Deposits And Other Assets Current Deposits and other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares outstanding, ending balance Number of shares outstanding, beginning balance Stock option, number of shares outstanding Assets, Current [Abstract] Current assets Number of common stock shares available for issuance Common Stock, Capital Shares Reserved for Future Issuance Interest Rate Cap [Member] 2017 Employee Stock Purchase Plan Two Thousand and Seventeen Employee Stock Purchase Plan [Member] Two thousand and seventeen employee stock purchase plan. Supplier Three Supplier Three Member Supplier three. Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value AVERAGE GRANT DATE FAIR VALUE, Forfeited Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Term Loan agreement, term Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Investment, Policy [Policy Text Block] Investments Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Fair Value, Recurring [Member] Fair Value, Measurements, Recurring Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Assets Measured at Fair Value on Recurring Basis Common Stock, Par or Stated Value Per Share Common stock, par value Royalty Accrued Royalties, Current Unrealized gain (loss) on short term investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on short-term investments Measurement Input Type [Domain] Accounts Receivable [Policy Text Block] Accounts Receivable Statement of Cash Flows [Abstract] Counterparty Name [Axis] Counterparty Name Debt issuance costs Adjustments To Debt Issuance Costs Adjustments to debt issuance costs. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase of shares Equity Components [Axis] Equity Components Share-based compensation arrangement by share-based payment award options forfeited. Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Number of options forfeited Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Net Loss Per Share of Common Stock Employee-related Liabilities, Current Employee compensation and related costs Employee-related Liabilities, Current, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Granted Computer Equipment [Member] Computer Equipment Valuation Approach and Technique [Axis] Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Subsequent Event Type [Axis] Labor London Interbank Offered Rates LIBOR [Member] London Interbank Offered Rates LIBOR [Member] Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Twenty twenty one ATM agreement. Twenty Twenty One A T M Agreement [Member] 2021 ATM Agreement Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free rate Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of restricted stock units outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Revenue Purchase and Sale Liability Revenue Purchase and Sale Liability [Member] Revenue purchase and sale liability. Amendment Flag Amendment Flag Operating Lease, Liability, Noncurrent Lease obligation - operating, long-term Corporate Debt Securities [Member] Corporate Bonds Accrued liabilities. Accrued Liabilities Disclosure [Text Block] Accrued Expenses Debt Instrument, Name [Domain] Debt Instrument, Name Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Embedded Derivative, Fair Value of Embedded Derivative Liability Fair value of embedded derivative liability Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR Net loss Net loss Number of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, Shares Number of shares exercised Operating Costs and Expenses Total operating expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Vested and exercisable, ending balance Variable Rate [Domain] Variable Rate Research and Development Expense [Member] Research and Development Customer [Domain] Debt Instrument, Interest Rate Terms Debt instrument, interest rate terms Schedule of Debt [Table Text Block] Schedule of Total Term Loan and Unamortized Debt Discount Schedule of Carrying Value of Debt Balance Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Other (expense) income Other income (expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of option granted Furniture and Fixtures [Member] Office Furniture Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total United States Government Agency securities US Government Corporations and Agencies Securities [Member] United States Government Agency Securities Proceeds from Stock Options Exercised Proceeds from the exercise of vested stock options Transfer of issuance costs from other current assets to equity Transfer of issuance costs from other current assets to equity. Unamortized debt discount Unamortized debt discount Debt Instrument, Unamortized Discount Less: discount Debt Instrument, Unamortized Discount, Total Allowance for excess, damaged and obsolete inventory Allowance for excess, damaged and obsolete inventory Allowance for excess, damaged and obsolete inventory. Restricted cash Restricted Cash, Current Issuance of warrants Fair value of warrants as an increase to additional paid-in capital Adjustments to Additional Paid in Capital, Warrant Issued Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock through employee stock purchase plan, Shares Number of common stock shares issued Short-Term Investments Short-term investments Short-term Investments, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise prices, forfeited Purchases. Purchases [Member] Purchases Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Supplier one. Supplier One Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] NUMBER OF SHARES Proceeds from revenue participation agreement, net Proceeds from Revenue Participation Agreement, Net Proceeds from revenue participation agreement, net. Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Weighted Average [Member] Weighted Average Antidilutive Securities [Axis] Antidilutive Securities Corporate Bonds Corporate Bond Securities [Member] Proceeds from sale of shares, Net Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Proceeds from offering Number of customer. Number of Customer Amortized period for expenses incurred for research and development outside united states Amortized Period for Expenses Incurred for Research and Development Outside United States Amortized period for expenses incurred for research and development outside united states. Credit agreement. Credit Agreement [Member] Credit Agreement Entity Interactive Data Current Entity Interactive Data Current Prepayment and legal fees Payment for Debt Extinguishment or Debt Prepayment Cost Marketable Securities [Table] Marketable Securities [Table] Customer one. Customer One [Member] Customer One Document Quarterly Report Document Quarterly Report Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash Cash and cash equivalents at beginning of period Statistical Measurement [Axis] Statistical Measurement Operating Lease, Cost Operating lease cost Debt Instrument, Periodic Payment, Principal Scheduled repayments outstanding Assets, Fair Value Disclosure Total Lease, Cost Total lease cost Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities Commercial Paper [Member] Commercial Paper Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Stock options, available for issuance Percentage of commission on gross sales proceeds. Percentage Of Commission On Gross Sales Proceeds Percentage of commission on gross sales proceeds Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value AVERAGE GRANT DATE FAIR VALUE, Granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Recognition period (in years) Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Contractual life Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Tranche B Loan. Tranche B Loan [Member] Tranche B Loan Entity Address, City or Town Entity Address, City or Town OCI Attributable to Parent [Member] Other Comprehensive Income (Loss) Equity [Abstract] Assets, Fair Value Disclosure [Abstract] Assets: Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Future Principal Payments Due Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSUs Forfeited RSUs Forfeited Long-term debt prepayment premium percentage after year two. Long Term Debt Prepayment Premium Percentage After Year Two Prepayment premium percentage after year two Interest Rate Floor [Member] Interest Rate Floor [Member] Prepayment premium percentage two Long Term Debt Prepayment Premium Percentage Year Two Long term debt prepayment premium percentage year two. Derivative Liability, Noncurrent Derivative liability Long-term debt prepayment premium percentage year one and two. Long Term Debt Prepayment Premium Percentage Year One And Two Prepayment premium percentage Depreciation Depreciation expense Depreciation, Total Weighted exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of common shares authorized for issuance Two thousand seventeen loan agreement. Two Thousand Seventeen Loan Agreement [Member] 2017 Loan Agreement Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Potential interest and penalties associated with uncertain tax positions, accruals Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Fair Value Disclosures [Abstract] Description Of Business And Basis Of Presentation [Line Items] Description Of Business And Basis Of Presentation [Line Items] Description of business and basis of presentation. Revenue purchase and sale liability Revenue Purchase and Sale Liability Revenue purchase and sale liability. Stock Issued During Period, Value, New Issues Issuance of common stock under at-the-market offering, net of issuance costs Common shares issued Supplier Concentration Risk [Member] Supplier Concentration Risk Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Debt instrument yield protection premium amount of principal percentage year three. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Three Yield protection premium percentage year three Liabilities, Current [Abstract] Current liabilities Lease Contractual Term [Axis] Lease Contractual Term Accounts Receivable Tranche B Warrant Tranche B Warrant [Member] Tranche B Warrant. Document Type Document Type On or Prior to December 31, 2024 Borrowings Three [Member] Borrowings three. Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Lease, Cost [Table Text Block] Schedule of Lease Cost and Other Information of Operating Lease Liabilities Statement of Stockholders' Equity [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Beginning balance Ending balance Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense Research and development Research and Development Expense, Total Settlement of restricted stock units for tax withholding obligations Payment, Tax Withholding, Share-Based Payment Arrangement Term loan Carrying value of term loan Long-term portion Term loan, long-term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional options granted Number of shares granted Long-term debt exit fee. Long Term Debt Exit Fee Exit fee Share based compensation arrangement by share based payment award options weighted average remaining contractual term. Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM Taxes paid. Taxes Paid Taxes paid Asset Class [Domain] Asset Class Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Commitments And Contingencies Line Items Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Subsequent Event Type [Domain] Lessee, Leases [Policy Text Block] Leases Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Estimated Fair Value of Options Valuation Assumptions Change in fair value of revenue purchase and sale liability Fair value adjustment to revenue purchase and sale liability Fair Value Adjustment to Revenue Purchase and Sale Liability Fair value adjustment to revenue purchase and sale liability. Underwriting agreement. Underwriting Agreement [Member] Underwriting Agreement Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price per share Warrant, exercise price Financial Instruments [Domain] Financial Instruments Sale of Stock [Axis] Sale of Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Up to Two Draws on or Prior to September 30, 2024 Borrowings Two [Member] Borrowings two. Up to Two Draws on or Prior to March 31, 2026 Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of RSU Activity Selling, General and Administrative Expense, Total Selling, General and Administrative Expense Selling, general and administrative Long-term debt final payment fee. Long Term Debt Final Payment Fee Final payment fee Credit Facility [Domain] Credit Facility Debt Instrument, Frequency of Periodic Payment Frequency of periodic payment Other Other Accrued Liabilities, Current Entity Address, Address Line Two Entity Address, Address Line Two Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounts Payable [Member] Accounts Payable Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from calculation of diluted net loss per share Financing costs Accrued financing related cost current. Accrued Financing Related Cost Current APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Accrued Liabilities, Current Accrued expenses Total accrued expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Exercise price per warrant Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Trading Symbol Trading Symbol Variable Rate [Axis] Variable Rate Equity, Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity AVERAGE GRANT DATE FAIR VALUE, Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Weighted Average Released Fair Value Share-based compensation arrangement by share-based payment award, equity instruments other than options, weighted average released fair value. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Class of Warrant or Right, Outstanding Prefunded warrant shares Other Liabilities, Noncurrent Other liabilities Other Liabilities, Noncurrent, Total Derivative Instrument [Axis] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Initial fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Discount Rate Measurement Input, Discount Rate [Member] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value of derivative

liability Stock option and incentive plan expiration date Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date Measurement Input Type [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Equity awards granted under the inducement , Granted Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Unrealized Losses Lease Agreement Require Standby Letter Of Credit Member Lease agreement require standby letter of credit. Lease Agreement Require Standby Letter Of Credit [Member] Lease Agreement Require Standby Letter of Credit Use of Estimates, Policy [Policy Text Block] Use of Estimates Proceeds from term loan, net Proceeds from Issuance of Long-Term Debt, Total Proceeds from Issuance of Long-Term Debt Proceeds from term loan Percentage of concentration risk Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Percentage of purchase price with related to purchaser revenue payment. Percentage Of Purchase Price With Related To Purchaser Revenue Payment Percentage of purchase price with related to purchaser revenue payment Sales returns and allowances and related costs Accrued Marketing Costs, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Security Exchange Name Security Exchange Name Counterparty Name [Domain] Counterparty Name Debt instrument yield protection premium amount of principal percentage after year three. Debt Instrument Yield Protection Premium Amount Of Principal Percentage After Year Three Yield protection premium percentage after year three Fair value adjustment to derivative liability. Fair Value Adjustment To Derivative Liability Fair value adjustment to derivative liability Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Fair Value Disclosures [Text Block] Fair Value of Financial Instruments December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value Fair market value per share of common stock Subsequent Event [Member] Subsequent Event Maximum [Member] Maximum Liabilities and Equity Total liabilities and stockholders' equity Two thousand nineteen ATM agreement. Two Thousand Nineteen A T M Agreement [Member] 2019 ATM Agreement Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) On Extinguishment of Debt, Total Operating Lease, Right-of-Use Asset Right-of-use lease assets - operating, net Short-term lease asset Prepaid Expense, Current Prepaid expenses Prepaid Expense, Current, Total Vested options, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Supplemental Cash Flow Information [Abstract] Supplemental cash flow information Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share - diluted Net loss per share, diluted Leasehold Improvements [Member] Leasehold Improvements Entity Ex Transition Period Entity Ex Transition Period Liabilities Total liabilities Payment of financing and stock issuance costs Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Total current assets Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Purchase shares of common stock Number of shares sold Issuance of common stock under at-the-market offering, net of issuance costs, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Stock option vesting term Entity Filer Category Entity Filer Category Long term debt prepayment premium amount. Long term debt prepayment premium amount Property, Plant and Equipment [Abstract] Deposits and other assets noncurrent . Deposits And Other Assets Noncurrent Deposits and other assets Deposits and other current assets Current Fiscal Year End Date Current Fiscal Year End Date 2024 ATM Agreement Twenty twenty four ATM agreement [Member] Twenty twenty four ATM agreement. Document [Domain] Change in fair value of term loan Fair value adjustment to term loan Fair Value Adjustment to Term Loan Fair value adjustment to term loan. Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Inventory in transit Accrued inventory in transit. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, outstanding ending balance Payment of final fee. Payment Of Final Fee Payment of final fee Entity Registrant Name Entity Registrant Name Incremental stock based compensation Share Based Compensation Arrangement By Share Based Payment Incremental Stock Based Compensation Share based compensation arrangement by share based payment incremental stock based compensation. Derivative Liability Derivative Liability [Member] Derivative Liability. Cost of Revenue, Total Cost of Revenue Cost of product revenues Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Earnings Per Share [Text Block] Net Loss per Share Debt Instrument, Maturity Date Loan agreement, maturity date Debt instrument, maturity date Entity Emerging Growth Company Entity Emerging Growth Company Operating lease expiration month and year. Operating Lease Expiration Month And Year Operating lease expiration month and year Relative fair value of detachable warrants. Relative Fair Value of Detachable Warrants Relative fair value of detachable warrants Other current liabilities Other Liabilities, Current Other Liabilities, Current, Total Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - basic Weighted-average shares used in computing net loss per share, basic Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Year ended: Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Common Stock, Shares Authorized Common stock, shares authorized Property, Plant and Equipment, Useful Life ESTIMATED USEFUL LIFE Sublease Income Sublease income Proceeds from Issuance of Common Stock Proceeds from at-the-market offering, net Concentration Risk Type [Axis] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets (Level 1) [Member] Long-term debt exit fee obligation accounted as derivative liability. Long Term Debt Exit Fee Obligation Accounted As Derivative Liability Derivative liability recorded against exit fee obligation Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Debt Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average exercise prices, vested and expected to vest ending balance Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise prices, granted Fair value of the term loan at issuance Fair value of term loan at issuance Fair value of term loan at issuance. Financial Instrument [Axis] Financial Instrument Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, outstanding Debt, Policy [Policy Text Block] Debt Issuance Costs General and Administrative Expense [Member] General and Administrative Schedule of Fair Value of Debt Balance Fair value of Debt Balance [Table Text Block] Fair value of debt balance. Revenue [Policy Text Block] Revenue Recognition Share-Based Payment Arrangement [Abstract] Embedded derivative liability upon issuance of Term Loan Embedded derivative liability upon issuance of Term Loan Oaktree Agreement Oaktree Agreement [Member] Oaktree agreement. Number of suppliers. Number of Suppliers Debt Securities, Available-for-Sale Fair Value Fair Value, Total Debt Securities, Available-for-sale, Total Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Information about Stock Option Activity Jefferies LLC. Jefferies L L C [Member] Jefferies Equity, Attributable to Parent [Abstract] Stockholders' equity Statement [Table] Statement [Table] Property, Plant and Equipment [Table Text Block] Schedule of Purchased Property and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested and expected to vest Inventory wrote off Inventory Write-down Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] WEIGHTED-AVERAGE EXERCISE PRICE Preferred Stock, Shares Authorized Preferred stock, shares authorized Revenue from Contract with Customer, Including Assessed Tax Product revenues, net Product revenues, net Securities Act File Number Entity File Number Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Share based compensation arrangement by share based payment award effective date. Share Based Compensation Arrangement By Share Based Payment Award Effective Date Stock option and incentive plan effective date Earnings Per Share [Abstract] Long-term debt increase on interest rate on default. Long Term Debt Increase On Interest Rate On Default Increase in interest rate on default Warrants and Rights Outstanding, Term Warrants exercise period Inventory Disclosure [Abstract] Supplier two. Supplier Two Lease Contractual Term [Domain] Lease Contractual Term Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense Interest Expense, Total Loss from operations Operating Income (Loss) Loss from operations Shares Issued, Price Per Share Selling price per share Selling price per share Debt instrument yield protection premium amount of principal percentage year one. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year One Yield protection premium percentage year one Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Letter Of Credit Member Letter of Credit [Member] Letter of Credit Entity Shell Company Entity Shell Company Document Information, Document [Axis] Accrued Professional Fees, Current Consulting and professional service fees Two thousand seventeen stock plan. Two Thousand Seventeen Stock Plan [Member] 2017 Stock Plan Debt Instrument, Interest Rate, Effective Percentage Debt instrument, effective interest rate Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Fair Value Option Fair Value of Financial Instruments, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested and exercisable Two thousand twenty three employment inducement award plan. Two Thousand Twenty Three Employment Inducement Award Plan [Member] 2023 Employment Inducement Award Plan Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Long-Term Debt, Type [Axis] Long-term Debt, Type Inventory Disclosure [Text Block] Inventory Initial draw amount Initial Draw Amount Initial draw amount. Document Fiscal Year Focus Document Fiscal Year Focus Preferred Stock, Value, Issued Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Principal payments on term loan Repayments of Long-Term Debt Repayments of Long-Term Debt, Total Revenue purchase and sale agreement. Revenue Purchase and Sale Agreement [Member] Revenue Purchase and Sale Agreement City Area Code City Area Code Operating leases expiration year. Operating Leases Expiration Year Operating leases expire Liabilities, Current Total current liabilities Initial fair value adjustment Liabilities, Fair Value Adjustment Derivative Contract [Domain] Two thousand nineteen loan agreement. Two Thousand Nineteen Loan Agreement [Member] 2019 Loan Agreement Inventory, net Inventory, Net, Total Inventory, Net Inventory, Finished Goods, Gross Finished goods Tranche A Loan. Tranche A Loan [Member] Tranche A Loan Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Schedule of accounting policies. Schedule Of Accounting Policies [Line Items] Schedule Of Accounting Policies [Line Items] Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Supplemental disclosure of non-cash activities Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Straight Line Basis Member Straight-line basis. Straight Line Basis [Member] Short-term Leases Recognized on Straight-line Basis Prepayment premium percentage one Long Term Debt Prepayment Premium Percentage Year One Long term debt prepayment premium percentage year one. Exit fee Business Exit Costs Long-term debt exit fee percentage. Long Term Debt Exit Fee Percentage Exit fee, percentage Income Tax, Policy [Policy Text Block] Income Taxes Commitments and Contingencies Disclosure [Abstract] Fair Value, by Balance Sheet Grouping [Table] Debt Securities, Available-for-Sale, Amortized Cost Cost Basis Amortized Cost, Total Operating Lease, Liability, Current Lease obligation - operating, short-term Short-term lease liability Document Information [Line Items] Debt Instrument, Interest Rate, Stated Percentage Interest rate, minimum Retained Earnings [Member] Accumulated Deficit Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Purchases of property and equipment Accrued Liabilities, Current [Abstract] Document Transition Report Document Transition Report Proceeds from common stock offering, net of underwriter discounts and offering costs Proceeds from common stock offering, net Proceeds From Follow On Offering Of Stock Proceeds from follow on offering of stock. Common stock additional shares price per share. Common Stock Additional Shares Price Per Share Common stock additional shares price per share December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Valuation Approach and Technique [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Deferred financing costs Adjustments to Additional Paid in Capital, Deferred financing costs Adjustments to additional paid in capital, deferred financing costs. Proceeds from Stock Plans Proceeds from employee stock purchase plan Weighted average exercise prices, exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Purchase price. Purchase Price Purchase price Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Minimum [Member] Minimum Common Stock [Member] Common Stock Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate intrinsic value, vested and expected to vest ending balance RSUs Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released in Period Share-based compensation arrangement by share-based payment award, equity instruments other than options, released in period AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Reduction in carrying value of operating right-of-use lease assets Reduction in carrying value of operating right-of-use lease assets Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid-in Capital [Member] Additional Paid-in Capital Common stock additional shares exercisable. Common Stock Additional Shares Exercisable Common stock additional shares exercisable Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Statement of Income Location, Balance [Domain] Income Statement Location December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Fair value of warrants issued Fair value of warrants issued Fair Value of Warrants Issued Fair value of warrants issued. Paid-in-Kind Interest Non-cash interest expense Performance Shares [Member] Performance Shares Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Maturities of short-term investments Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Increase decrease in operating lease payments. Increase Decrease In Operating Lease Payments Operating cash flows from operating leases Underwritten public offering. Underwritten Public Offering [Member] Underwritten Public Offering Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Supplier [Axis] Common stock, \$0.0001 par value; 150,000,000 shares authorized as of September 30, 2024; 35,968,510 and 50,040,134 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Total Common stock, \$0.0001 par value; 150,000,000 shares authorized as of June 30, 2024; 35,968,510 and 36,139,802 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively Debt instrument yield protection premium amount of principal percentage year two. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Two Yield protection premium percentage year two Payment of term loan final fee Payment Of Term Loan Final Fee Payment of term loan final fee. Investment Income, Interest Interest income Long-term debt amortization of final payment fee. Long Term Debt Amortization Of Final Payment Fee Amortization of final payment fee SLR Investment Corp And Silicon Valley Bank S L R Investment Corp And Silicon Valley Bank [Member] SLR Investment Corp. and Silicon Valley Bank Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Revenue from Contract with Customer Benchmark [Member] Revenue Customer Two Customer Two [Member] Customer two. Customer Three Customer three. Operating Lease, Liability Total Operating Lease, Liability, Total Measurement Frequency [Axis] Measurement Frequency Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Commitments and Contingencies Commitments and contingencies (Note 12) trailing 12-month net sales. Trailing of net sales Marketable Securities [Line Items] Marketable Securities [Line Items] Schedule of cash cash equivalents and restricted cash. Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of Cash, Cash Equivalents and Restricted Cash Weighted Average Number of Shares

Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding - diluted Weighted-average shares used in computing net loss per share, diluted Significant Accounting Policies [Text Block] Significant Accounting Policies Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs, Shares Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs Shares Issuance of common stock and prefunded warrants in common stock offering net of issuance costs shares. Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest, ending balance Future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Total minimum lease payments Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Inventory Two thousand fourteen stock plan. Two Thousand Fourteen Stock Plan [Member] 2014 Stock Plan Concentration Risk Benchmark [Domain] Accrued contract research and development expense current. Accrued Contract Research And Development Expense Current Contract research and development Amortized period for expenses incurred for research and development in united states Amortized Period for Expenses Incurred for Research and Development in United States Amortized period for expenses incurred for research and development in united states. Entity Small Business Entity Small Business Debt Instrument, Basis Spread on Variable Rate Basis spread on variable base rate Financial Liabilities Debt Disclosure [Text Block] Debt Manufacturing costs Accrued Manufacturing Costs Accrued manufacturing costs. United States Treasury securities US Treasury Securities [Member] United States Treasury Securities Investments, Fair Value Disclosure Investments Investments, Fair Value Disclosure, Total Supplier [Domain] Credit Facility [Axis] Credit Facility Vesting of restricted stock, Shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on investments Accretion on short-term investments At the market offering. At The Market Offering [Member] At The Market Offering Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise prices, outstanding ending balance Weighted average exercise prices, outstanding beginning balance Amortization of Debt Discount (Premium) Amortization of debt discount Schedule Of Accounting Policies [Table] Schedule of accounting policies. Schedule Of Accounting Policies [Table] Asset Class [Axis] Asset Class Proceeds from (Repayments of) Debt, Total Proceeds from (Repayments of) Debt Proceeds from (Repayments of) Debt, Total Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Change in fair value of the term loan Change in fair value of term loan Change in fair value of term loan. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating right-of-use asset received in exchange for lease obligations Measurement Frequency [Domain] Measurement Frequency Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs Issuance of common stock and prefunded warrants in common stock offering net of issuance costs. Inventory, Work in Process, Gross Work-in-process Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) [Member] Significant Unobservable Inputs (Level 3) [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - operating leases Legal accounting and other costs. Legal Accounting And Other Costs [Member] Legal Accounting and Other Costs Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Liabilities, Fair Value Disclosure, Total Liabilities, Fair Value Disclosure Total Short-Term Lease, Cost Short-term lease cost XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep 30, 2024 Nov. 12, 2024 Document Information [Line Items] Á Á Document Type 10-Q Á Amendment Flag false Á Document Period End Date Sep. 30, 2024 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q3 Á Trading Symbol SCPH Á Entity Registrant Name SCPHARMACEUTICALS INC. Á Entity Central Index Key 0001604950 Á Current Fiscal Year End Date -12-31 Á Entity Filer Category Non-accelerated Filer Á Entity Current Reporting Status Yes Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Shell Company false Á Entity Interactive Data Current Yes Á Title of 12(b) Security Common stock, par value \$0.0001 per share Á Security Exchange Name NASDAQ Á Entity File Number 001-38293 Á Entity Incorporation, State or Country Code DE Á Entity Tax Identification Number 46-5184075 Á Entity Address, Address Line One 25 Mall Road Á Entity Address, Address Line Two Suite 203 Á Entity Address, City or Town Burlington Á Entity Address, State or Province MA Á Entity Address, Postal Zip Code 01803 Á City Area Code 617 Á Local Phone Number 517-0730 Á Document Quarterly Report true Á Document Transition Report false Á Entity Common Stock, Shares Outstanding 50,040,134 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a-1> + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Á Á Cash and equivalents \$91,484 \$ 46,814 Short-term investments Á 29,199 Accounts receivable, net 9,217 4,489 Inventory, net 18,107 8,840 Prepaid expenses 3,373 2,436 Deposits and other current assets 1,148 1,160 Total current assets 123,329 92,938 Property and equipment, net 51 58 Right-of-use lease assets - operating, net 1,330 1,401 Deposits and other assets 359 82 Total assets 125,069 94,479 Current liabilities Á Á Accounts payable 5,003 4,001 Accrued expenses 9,868 8,901 Lease obligation - operating, short-term 231 176 Other current liabilities 162 56 Total current liabilities 15,264 13,134 Term loan, long-term 51,099 38,811 Revenue purchase and sale liability 26,830 0 Derivative liability 0 3,857 Lease obligation - operating, long-term 1,167 1,282 Other liabilities 0 177 Total liabilities 94,360 57,261 Commitments and contingencies (Note 12) Stockholders' equity Á Á Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding Common stock, \$0.0001 par value; 150,000,000 shares authorized as of September 30, 2024; 35,968,510 and 50,040,134 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively 5 4 Additional paid-in capital 378,353 318,561 Accumulated deficit (347,649) (281,346) Accumulated other comprehensive income Á (1) Total stockholders' equity 30,709 37,218 Total liabilities and stockholders' equity \$ 125,069 \$ 94,479 X - DefinitionDeposits and other assets current. + ReferencesNo definition available. + Details Name: scph DepositsAndOtherAssetsCurrent Namespace Prefix: scph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDeposits and other assets noncurrent. + ReferencesNo definition available. + Details Name: scph DepositsAndOtherAssetsNoncurrent Namespace Prefix: scph_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRevenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph RevenuePurchaseAndSaleLiability Namespace Prefix: scph_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10) + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)

Subparagraph (g) - Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap PrepaidExpenseCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap ShortTermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: per Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Å Å Preferred stock, par value \$ 0.0001 \$ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value \$ 0.0001 \$ 0.0001 Common stock, shares authorized 150,000,000 150,000,000 Common stock, shares issued 50,040,134 35,968,510 Common stock, shares outstanding 50,040,134 35,968,510 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dt:types:perShareItemBalanceType: per Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dt:types:perShareItemBalanceType: per Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalanceType: per Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalanceType: per Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Å Å Å Å Å Å Product revenues, net \$ 10,026 \$ 3,796 \$ 24,182 \$ 7,497 Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember Operating expenses: Å Å Å Cost of product revenues \$ 3,311 \$ 1,079 \$ 7,396 \$ 2,038 Research and development 3,541 3,421 8,944 8,471 Selling, general and administrative 21,320 14,135 56,275 37,127 Total operating expenses 28,172 18,635 72,615 47,636 Loss from operations (18,146) (14,839) (48,433) (40,139) Loss on extinguishment of debt (13,032) Å (13,032) Å Change in fair value of term loan (2,954) Å (2,954) Å Change in fair value of revenue purchase and sale liability (1,830) Å (1,830) Å Other (expense) income 1,804 (36) 3,587 1,193 Interest income 903 1,301 2,444 3,979 Interest expense (1,850) (2,060) (6,085) (6,031) Net loss \$ (35,105) \$ (15,634) \$ (66,303) \$ (40,998) Net loss per share - basic \$ (0.75) \$ (0.41) \$ (1.6) \$ (1.07) Net loss per share - diluted \$ (0.75) \$ (0.41) \$ (1.6) \$ (1.07) Weighted average common shares outstanding - basic 46,558,474 38,760,895 41,516,917 38,421,676 Weighted average common shares outstanding - diluted 46,558,474 38,760,895 41,516,917 38,421,676 Other comprehensive loss: Å Å Å Unrealized gain (loss) on short term investments Å \$ 4 \$ 1 \$ (34) Comprehensive loss \$ (35,105) \$ (15,630) \$ (66,302) \$ (41,032) X - DefinitionFair value adjustment to revenue purchase and sale liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: scph FairValueAdjustmentToRevenuePurchaseAndSaleLiability Namespace Prefix: scph Data Type: xbrli:monetaryItemBalanceType: debit Period Type: duration X - DefinitionFair value adjustment to term loan. + ReferencesNo definition available. + Details Name: scph FairValueAdjustmentToTermLoan Namespace Prefix: scph Data Type: xbrli:monetaryItemBalanceType: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-

[http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8): [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9): <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12): [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15): [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17>: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37):

FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrl:sharesItem Type Balance Type: na Period Type: duration XML ID: R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD (\$) in Thousands Total Common Stock Additional Paid-in Capital Accumulated Deficit Other Comprehensive Income (Loss) Beginning Balance at Dec. 31, 2022 \$ 27,433 \$ 3 \$ 298,934 \$ (226,536) \$ 32 Beginning Balance, Shares at Dec. 31, 2022 \$ 34,257,916 \$ 4 \$ Net loss (11,210) \$ 4 (11,210) \$ 4 Issuance of common stock under at-the-market offering, net of issuance costs 13,628 \$ 1 13,627 \$ 4 Issuance of common stock under at-the-market offering, net of issuance costs, Shares \$ 1,511,157 \$ 4 \$ Stock-based compensation 980 \$ 980 \$ 4 Unrealized gain (loss) on short term investments (24) \$ 4 (24) Ending Balance at Mar. 31, 2023 75,807 \$ 4 313,541 (237,746) 8 Ending Balance, Shares at Mar. 31, 2023 35,769,073 \$ 4 \$ Beginning Balance at Dec. 31, 2022 7,433 \$ 3 298,934 (226,536) 32 Beginning Balance, Shares at Dec. 31, 2022 34,257,916 \$ 4 \$ Net loss (40,998) \$ 4 \$ Unrealized gain (loss) on short term investments (34) \$ 4 \$ 4 Ending Balance at Sep. 30, 2023 49,146 \$ 4 316,678 (267,534) (2) Ending Balance, Shares at Sep. 30, 2023 35,859,045 \$ 4 \$ Beginning Balance at Mar. 31, 2023 75,807 \$ 4 313,541 (237,746) 8 Beginning Balance, Shares at Mar. 31, 2023 35,769,073 \$ 4 \$ Net loss (14,154) \$ 4 (14,154) \$ 4 Issuance of common stock upon exercise of stock options 101 \$ 101 \$ 4 Issuance of common stock upon exercise of stock options, Shares \$ 18,000 \$ 4 \$ Issuance of common stock under at-the-market offering, net of issuance costs 332 \$ 332 \$ 4 Issuance of common stock under at-the-market offering, net of issuance costs, Shares \$ 33,333 \$ 4 \$ Stock-based compensation 1,179 \$ 1,179 \$ 4 Unrealized gain (loss) on short term investments (14) \$ 4 (14) Issuance of common stock through employee stock purchase plan 176 \$ 176 \$ 4 Issuance of common stock through employee stock purchase plan, Shares \$ 29,076 \$ 4 \$ 4 Ending Balance at Jun. 30, 2023 63,427 \$ 4 315,329 (251,900) (6) Ending Balance, Shares at Jun. 30, 2023 35,849,482 \$ 4 \$ Net loss (15,634) \$ 4 (15,634) \$ 4 Issuance of common stock upon exercise of stock options 68 \$ 68 \$ 4 Issuance of common stock upon exercise of stock options, Shares \$ 9,563 \$ 4 \$ 4 Stock-based compensation 1,281 \$ 1,281 \$ 4 Unrealized gain (loss) on short term investments 4 \$ 4 \$ 4 Ending Balance at Sep. 30, 2023 49,146 \$ 4 316,678 (267,534) (2) Ending Balance, Shares at Sep. 30, 2023 35,859,045 \$ 4 \$ Beginning Balance at Dec. 31, 2023 37,218 \$ 4 318,561 (281,346) (1) Beginning Balance, Shares at Dec. 31, 2023 35,968,510 \$ 4 \$ Net loss (14,108) \$ 4 (14,108) \$ 4 Issuance of common stock upon exercise of stock options 181 \$ 181 \$ 4 Issuance of common stock upon exercise of stock options, Shares \$ 32,754 \$ 4 \$ Vesting of restricted stock (166) \$ (166) \$ 4 Vesting of restricted stock, Shares \$ 53,145 \$ 4 \$ 4 Stock-based compensation 1,440 \$ 1,440 \$ 4 Unrealized gain (loss) on short term investments 1 \$ 1 \$ 1 Ending Balance at Mar. 31, 2024 24,566 \$ 4 320,016 (295,454) \$ 4 Ending Balance, Shares at Mar. 31, 2024 36,054,409 \$ 4 \$ Beginning Balance at Dec. 31, 2023 37,218 \$ 4 318,561 (281,346) \$ (1) Beginning Balance, Shares at Dec. 31, 2023 35,968,510 \$ 4 \$ Net loss \$ (66,303) \$ 4 \$ 4 Issuance of common stock upon exercise of stock options, Shares 30,203 \$ 4 \$ 4 Unrealized gain (loss) on short term investments \$ 1 \$ 1 \$ 4 Ending Balance at Sep. 30, 2024 30,709 \$ 5 378,353 (347,649) \$ 4 Ending Balance, Shares at Sep. 30, 2024 50,040,134 \$ 4 \$ Beginning Balance at Mar. 31, 2024 24,566 \$ 4 320,016 (295,454) \$ 4 Beginning Balance, Shares at Mar. 31, 2024 36,054,409 \$ 4 \$ Net loss (17,090) \$ 4 (17,090) \$ 4 Stock-based compensation 1,491 \$ 1,491 \$ 4 Issuance of common stock through employee stock purchase plan 283 \$ 283 \$ 4 Issuance of common stock through employee stock purchase plan, Shares \$ 85,393 \$ 4 \$ 4 Ending Balance at Jun. 30, 2024 9,250 \$ 4 321,790 (312,544) \$ 4 Ending Balance, Shares at Jun. 30, 2024 36,139,802 \$ 4 \$ Net loss (35,105) \$ 4 (35,105) \$ 4 Issuance of warrants 1,744 \$ 1,744 \$ 4 Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs 53,547 \$ 1 53,546 \$ 4 Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs, Shares \$ 13,875,000 \$ 4 \$ 4 Issuance of common stock upon exercise of stock options 47 \$ 47 \$ 4 Issuance of common stock upon exercise of stock options, Shares \$ 21,792 \$ 4 \$ 4 Vesting of restricted stock, Shares \$ 3,540 \$ 4 \$ 4 Stock-based compensation 1,226 \$ 1,226 \$ 4 Ending Balance at Sep. 30, 2024 \$ 30,709 \$ 5 \$ 378,353 (347,649) \$ 4 Ending Balance, Shares at Sep. 30, 2024 50,040,134 \$ 4 \$ X - Definition-Issuance of common stock and pre-funded warrants in common stock offering net of issuance costs. + ReferencesNo definition available. + Details Name: scph_IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCosts Namespace Prefix: scph Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock and pre-funded warrants in common stock offering net of issuance costs shares. + ReferencesNo definition available. + Details Name: scph_IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCostsShares Namespace Prefix: scph Data Type: xbrl:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08)(g)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2003/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap ProfitLoss Namespace Prefix: us-gaap Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap SharesOutstanding Namespace Prefix: us-gaap Data Type: xbrl:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section

S99 - Paragraph 3 - Subparagraph (SX 210.6-09(4)(b)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 10 - Name Accounting Standards Codification -Section S99 -Paragraph 3 - Subparagraph (SX 210.6-03(i)(1)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 505 - SubTopic 10 - Name Accounting Standards Codification -Section S99 - Paragraph 1 - Subparagraph (SX 210.3-04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(28)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.3-04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(28)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.6-09(4)(b)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 505 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 - Subparagraph (SX 210.3-04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.3-04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(28)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.3-04) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(30)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(31)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef - Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef - Topic 946 - SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 - Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.6-04(19)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 - Subparagraph (SX 210.6-05(4)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 - Subparagraph (SX 210.6-09(6)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 - Subparagraph (SX 210.6-09(7)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(ii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 - Subparagraph (SAB Topic 4.E) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD (\$) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2023 Sep. 30, 2023 Cash flows from operating activities Á Á Á Á Á Net loss \$ (35,105,000) \$ (14,108,000) \$ (15,634,000) \$ (11,210,000) \$ (66,303,000) \$ (40,998,000) Á Adjustments to reconcile net loss to cash used in operating activities Á Á Á Á Á Depreciation expense 5,000 Á 6,000 Á 16,000 18,000 Á Reduction in carrying value of operating right-of-use lease assets Á Á Á Á 71,000 468,000 Á Accretion on short-term investments Á Á Á Á (120,000) (1,570,000) Á Allowance for excess, damaged and obsolete inventory Á Á Á Á 75,000 Á 0 Stock-based compensation Á Á Á Á 4,157,000 3,440,000 Á Non-cash interest expense Á Á Á Á 1,562,000 1,576,000 Á Fair value adjustment to derivative liability Á Á Á Á (3,857,000) (1,214,000) Á Fair value adjustment to term loan 2,954,000 Á Á 2,954,000 Á Fair value adjustment to revenue purchase and sale liability 1,830,000 Á Á 1,830,000 Á Debt issuance costs Á Á Á Á 4,487,000 Á Á Loss on extinguishment of debt 13,032,000 Á Á 13,032,000 Á Changes in operating assets and liabilities Á Á Á Á Accounts receivable Á Á Á Á (4,728,000) (4,175,000) Á Inventory Á Á Á Á (9,343,000) (5,893,000) Á Prepaid expenses and other assets Á Á Á Á (1,203,000) 867,000 Á Accounts payable, accrued expenses and other liabilities Á Á Á Á 2,018,000 3,395,000 Á Net cash used in operating activities Á Á Á Á (55,352,000) (44,086,000) Á Cash flows from investing activities Á Á Á Á Á Purchases of property and equipment Á Á Á Á (9,000) (3,000) Á Maturities of short-term investments Á Á Á Á 29,320,000 44,100,000 Á Purchases of short-term investments Á Á Á Á (50,595,000) Á Net cash (used in) provided by investing activities Á Á Á Á 29,311,000 (6,498,000) Á Cash flows from financing activities Á Á Á Á Á Proceeds from common stock offering, net of underwriter discounts and offering costs Á Á Á Á 53,547,000 Á Proceeds from term loan, net Á Á Á Á 46,772,000 Á Proceeds from revenue participation agreement, net Á Á Á Á 23,629,000 Á Proceeds from employee stock purchase plan Á Á Á Á 283,000 176,000 Á Proceeds from the exercise of vested stock options Á Á Á Á 228,000 169,000 Á Proceeds from at-the-market offering, net Á Á Á Á 14,038,000 Á Principal payments on term loan Á Á Á Á (50,000,000) Á Prepayment and legal fees Á Á Á Á (2,582,000) Á Payment of term loan final fee Á Á Á Á (1,000,000) Á Settlement of restricted stock units for tax withholding obligations Á Á Á Á (166,000) Á Net cash provided by financing activities Á Á Á Á 70,711,000 14,383,000 Á Net (decrease) increase in cash and cash equivalents Á Á Á Á 44,670,000 (36,201,000) Á Cash and cash equivalents at beginning of period Á Á Á Á 46,814,000 Á 71,243,000 46,814,000 71,243,000 Cash and cash equivalents at end of period \$ 91,484,000 Á \$ 35,042,000 Á 91,484,000 35,042,000 Á Supplemental cash flow information Á Á Á Á Á Interest paid Á Á Á Á 4,556,000 4,455,000 Á Taxes paid Á Á Á Á 174,000 196,000 Á Supplemental disclosure of non-cash activities Á Á Á Á Á Fair value of warrants issued Á Á Á Á 1,855,000 Á Transfer of issuance costs from other noncurrent assets to equity Á Á Á Á 79,000 Á Operating right-of-use asset received in exchange for lease obligations Á Á Á Á \$ 71,000 \$ 1,437,000 Á X - DefinitionAdjustments to debt issuance costs. + ReferencesNo definition available. + Details Name: scph_AdjustmentsToDebtIssuanceCosts Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAllowance for excess, damaged and obsolete inventory. + ReferencesNo definition available. + Details Name: scph_AllowanceForExcessDamagedAndObsoleteInventory Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to derivative liability. + ReferencesNo definition available. + Details Name: scph_FairValueAdjustmentToDerivativeLiability Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to revenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph_FairValueAdjustmentToRevenuePurchaseAndSaleLiability Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to term loan. + ReferencesNo definition available. + Details Name: scph_FairValueAdjustmentToTermLoan Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value of warrants issued. + ReferencesNo definition available. + Details Name: scph_FairValueOfWarrantsIssued Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionPayment of term loan final fee. + ReferencesNo definition available. + Details Name: scph_PaymentOfTermLoanFinalFee Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionProceeds from follow on offering of stock. + ReferencesNo definition available. + Details Name: scph_ProceedsFromFollowOnOfferingOfStock Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from revenue participation agreement, net. + ReferencesNo definition available. + Details Name: scph_ProceedsFromRevenueParticipationAgreementNet Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionTaxes paid. + ReferencesNo definition available. + Details Name: scph_TaxesPaid Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionTransfer of issuance costs from other noncurrent assets to equity. + ReferencesNo definition available. + Details Name: scph_TransferOfIssuanceCostsFromOtherNoncurrentAssetsToEquity Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and

so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <https://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4> + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of right-of-use asset from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap_PaymentsOfDebtExtinguishmentCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 10: <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name>

Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability, + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement, + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available, + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD (\$) (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Pay vs Performance Disclosure Á Á Á Net Income (Loss) \$ (35,105) \$ (15,634) \$ (66,303) \$ (40,998) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PyPTable Namespace Prefix: ecd_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent, + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Á Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph a + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Á Description of Business and Basis of Presentation 1, Description of Business and Basis of PresentationDescription of BusinessscPharmaceuticals LLC was formed as a limited liability company under the laws of the State of Delaware on February 19, 2013. On March 24, 2014, scPharmaceuticals LLC was converted to a Delaware corporation and changed its name to scPharmaceuticals Inc. (â€œthe Companyâ€). The Company is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Companyâ€™s strategy is

designed to enable the subcontracted administration of therapies that have previously been limited to intravenous (i.v.) delivery. The Company's headquarters and primary place of business is Burlington, Massachusetts. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (GAAP) for interim financial information and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary, scPharmaceuticals Securities Corporation. Certain information and disclosures normally included in financial statements in accordance with U.S. GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2024. The Company has determined that it operates in one segment. The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2023 and 2024 and condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2024 are unaudited. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with that used to prepare the Company's audited annual financial statements and include, in the opinion of management, adjustments, consisting of normal recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full year ending December 31, 2024. As of September 30, 2024, the Company had an accumulated deficit of approximately \$347.6 million. Management expects to continue to incur operating losses for the foreseeable future. The Company has financed its operations to date from proceeds from the sale of common stock, preferred stock and the incurrence of debt. As of September 30, 2024, the Company had cash and cash equivalents of \$91.5 million. On October 13, 2022, the Company entered into a Credit Agreement and Guaranty (the "Oaktree Agreement") with, among others, the lenders from time to time party thereto and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the lenders (Note 9). On August 9, 2024 (the "Closing Date"), the Company entered into a Credit Agreement and Guaranty (the "Credit Agreement") with the guarantors from time to time party thereto, the lenders from time to time party thereto (the "Lenders"), and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lenders (in such capacity, the "Agent") (Note 9). On the Closing Date, the Company also entered into a Revenue Participation Right Purchase and Sale Agreement (the "Revenue Purchase and Sale Agreement") with Perceptive Credit Holdings IV, LP (the "Purchaser") (Note 9). The Company used the proceeds of the Credit Agreement and the Revenue Purchase and Sale Agreement to, on the Closing Date, prepay all outstanding obligations under the Oaktree Agreement, including the payment of fees and expenses associated with the Oaktree Agreement. In addition, on August 13, 2024, the Company completed an underwritten public offering of shares of its common stock (and, in lieu of such shares of common stock to selected investors, pre-funded warrants to purchase shares of its common stock) with net proceeds of \$53.5 million (Note 10). The Company's existing cash and cash equivalents will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. Additionally, the Company expects to have access to funds pursuant to an at-the-market offering program with Cowen and Company, LLC (Note 10), or could otherwise seek additional funding through a combination of public or private equity offerings if it believes additional resources are needed. Additional financing may not be available on a timely basis on terms acceptable to the Company, or at all. X - Definition The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent> Reference 3:

Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1:

-Paragraph 11 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-II + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] A Stockholders' Equity 10. Stockholders' Equity 2021 At-the-Market Issuance Sales Agreement On March 23, 2021, the Company entered into an Open Market Sale Agreement (the "2021 ATM Agreement") with Cowen and Company, LLC ("Cowen&C") with respect to an at-the-market offering program under which the Company could offer and sell shares of its common stock (the "2021 ATM Shares"), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent. The Company agreed to pay Cowen a commission up to 3.0% of the gross sales proceeds of such 2021 ATM Shares. On March 13, 2024, the Company amended and restated the 2021 ATM Agreement and entered into a new \$50.0 million Open Market Sales Agreement with Cowen (the "2024 ATM Agreement"). As of March 13, 2024, the Company had sold a total of 1,726,043 2021 ATM Shares under the 2021 ATM Program at a weighted average gross selling price of \$9.01 per share for net proceeds of \$15.2 million. 2024 At-the-Market Issuance Sales Agreement Pursuant to the 2024 ATM Agreement, the Company could offer and sell shares of its common stock (the "2024 ATM Shares"), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent (the "2024 ATM Program"). The offering and sale of the 2024 ATM Shares will be made pursuant to the Company's shelf registration statement on Form S-3, which was declared effective by the SEC on March 22, 2024 (the "2024 Registration Statement"). There were no shares issued under the 2024 ATM Program as of September 30, 2024. Sale of Common Stock On August 13, 2024, the Company completed an underwritten public offering of 13,875,000 shares of its common stock, \$0.0001 par value per share (the "2024 Offering Shares"), and, in lieu of shares of common stock to certain select investors, pre-funded warrants to purchase up to an aggregate of 500,000 shares of common stock at an exercise price equal to \$0.001 per share, pursuant to the 2024 Registration Statement. The 2024 Offering Shares were sold at an offering price of \$4.00 per share. The pre-funded warrants were sold at an offering price of \$3.999 per underlying share, which was equal to the price per share of common stock being sold in this offering, minus \$0.001, which is the exercise price per share of the pre-funded warrants. The pre-funded warrants were accounted for as equity instruments. Net proceeds of the offering were \$53.5 million, after deducting underwriting discounts, commissions and offering expenses. X - References No definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1Reference 10: http://asc.fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Stock-Based Compensation 11. Stock-Based Compensation Stock Options The Company's 2017 Stock Option and Incentive Plan (the "2017 Stock Plan") became effective in November 2017, upon the closing of the Company's initial public offering and will expire in October 2027. Under the 2017 Stock Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards. The Company's 2014 Stock Incentive Plan (the "2014 Stock Plan") was terminated in November 2017 effective upon the completion of the Company's initial public offering and no further options will be granted under the 2014 Stock Plan. At September 30, 2024, there were 555,427 options outstanding under the 2014 Stock Plan. As of September 30, 2024, there were 8,769,977 shares of the Company's common stock authorized for issuance under the 2017 Stock Plan, including 366,823 options that have been forfeited from the 2014 Stock Plan. At September 30, 2024, there were 3,206,310 options available for issuance under the 2017 Stock Plan, 4,775,676 options outstanding and 721,766 RSUs outstanding. On February 1, 2023, the Board of Directors of the Company adopted the 2023 Employment Inducement Award Plan (the "Inducement Plan") and, subject to the adjustment provisions of the Inducement Plan, reserved 500,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the Inducement Plan. At September 30, 2024, there were 385,628 options available for issuance under the Inducement Plan, and 114,372 options outstanding. Awards granted under the 2017 Stock Plan and the Inducement Plan have a term of ten years. Vesting of awards under the 2017 Stock Plan and Inducement Plan is determined by the board of directors, but is generally over one to four-year terms. The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions: A A Nine Months Ended September 30, 2023 A A 2023 A A 2024 A A Risk-free interest rate A 3.40% - 4.23% A A 3.66% - 4.59% A A Expected dividend yield A 0% A A 0% A A Expected life A 5.5-6.98 years A A 5.5-6.7 years A A Expected volatility A 77%-85% A A 76%-79% A A Weighted-average grant date fair value A \$ 5.36 A A \$ 3.81 A A The following table summarizes information about stock option activity during the nine months ended September 30, 2024 (in thousands, except share and per share data): A A NUMBER OF SHARES A A WEIGHTED-AVERAGE EXERCISE PRICE A A WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM A A AGGREGATE INTRINSIC VALUE A A Outstanding, December 31, 2023 A A 4,681,326 A A \$ 6.09 A A A A A A Granted A A 1,119,772 A A A A 5.43 A A A A A A Exercised A A (30,203) A A 2.85 A A A A A A Forfeited A A (325,420) A A 6.46 A A A A A A Outstanding, September 30, 2024 A A 5,445,475 A A A A 5.95 A A A A 6.81 A A A A 7.25 A A Vested and exercisable, September 30, 2024 A A 3,517,499 A A \$ 6.15 A A A A 5.76 A A A A 6.06 A A Vested and expected to vest, September 30, 2024 A A 5,081,614 A A A A 5.98 A A A A 6.66 A A A A 7.09 A A A A 24,343 options were exercised on December 29, 2023 and the shares settled on January 2, 2024. The share issuance has been recognized on the Company's Condensed Consolidated Statements of Stockholders' Equity for the quarter ending March 31, 2024. The following table summarizes information about RSU activity during the nine months ended September 30, 2024: A A RSUs A A AVERAGE GRANT DATE FAIR VALUE (IN DOLLARS PER SHARE) A A RSUs outstanding, December 31, 2023 A A 368,411 A A \$ 6.33 A A Granted A A 471,790 A A A A 5.70 A A Released A A (82,818) A A A A 6.33 A A Forfeited A A (35,617) A A A A 6.24 A A RSUs outstanding at September 30, 2024 A A 721,766 A A A A 5.93 A A A Unrecognized compensation expense related to unvested options as of September 30, 2024 was \$5.2 million and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 2.3 years. Unrecognized compensation expense related to unvested RSUs as of September 30, 2024 was \$2.4 million and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 3.0 years. A Employee Stock Purchase Plan In October 2017, the board of directors approved the 2017 Employee Stock Purchase Plan (the "ESPP") which became effective in November 2017, upon the closing of the Company's IPO. As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. Eligible employees who elected to participate were able to participate in the ESPP beginning September 1, 2021. During the nine months ended September 30, 2024, 85,393 shares were issued under the ESPP. As of September 30, 2024, there were 1,377,173 shares of common stock available for issuance under the ESPP. The Company recorded stock-based compensation expense in the following expense categories of its accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2024 (in thousands): A A Three Months Ended September 30, A A Nine Months Ended September 30, A A 2023 A A 2024 A A 2023 A A 2024 A A Research and development A A \$ 370 A A A A \$ 1,075 A A A A \$ 1,160 A A General and administrative A A 911 A A A A 842 A A A A 2,365 A A Total A A \$ 1,281 A A A A \$ 1,227 A A A A 3,440 A A A A X - Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] A Commitments and Contingencies 12. Commitments and Contingencies Operating Leases The Company leases office facilities and equipment under long-term, non-cancelable operating lease agreements. The leases expire at various dates through 2029 and do not include renewal options. Certain leases provide for increases in future minimum annual rental payments as defined in the lease agreements. The leases generally also include real estate taxes and common area maintenance charges in the annual rental payments. Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2024 (in thousands): A Year ended: A A December 31, 2024 A A \$ 96 A A December 31, 2025 A A \$ 381 A A December 31, 2026 A A \$ 376 A A December 31, 2027 A A \$ 358 A A December 31, 2028 A A \$ 367 A A Thereafter A A \$ 249 A A Total minimum lease payments A A 1,827 A A Less imputed interest A A (429) A A Total A A \$ 1,398 A A A A Nine Months Ended September 30, A A 2023 A A 2024 A A Lease cost: A A A A A A Operating lease cost A A \$ 497 A A A A 261 A A Short-term lease cost A A 28 A A A A 35 A A Total lease cost A A \$ 525 A A A A 296 A A Other information A A A A A A Cash paid for amounts included in the measurement of lease liabilities A A \$ 489 A A A A 258 A A Operating cash flows from operating leases A A \$ 8 A A A A 10 A A Weighted-average remaining lease term - operating leases A A 5.5a years A A 4.8a years A A Weighted-average discount rate - operating leases A A 11.6% A A 12.1% A A Research and Development Agreements As part of the Company's research and development efforts, the Company enters into research and development agreements with certain companies. These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company. Some of these agreements also contain provisions which require the Company to make payments for exclusivity in the development of products in the area of loop diuretics. X - References No definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://asc.fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Use of Estimates Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and Cash Equivalents Cash and cash equivalents consists of bank deposits and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company's cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Accounts Receivable Accounts Receivable Accounts receivable are recorded net of any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material credit loss allowance for uncollectible trade receivables. Concentration of Credit Risk Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold a minimum rating,

thereby reducing credit risk exposure. The Company has a limited number of specialty pharmacy customers and distributors. As of December 31, 2023 and September 30, 2024, three customers represented 99% and two customers represented 98% of accounts receivable, respectively. For the three and nine months ended September 30, 2024, two customers represented 98% and three customers represented 99% of revenue, respectively. For the three and nine months ended September 30, 2023, two customers represented 92% and one customer represented 88% of revenue, respectively. The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024, one supplier represented 47% and three suppliers represented 49% of accounts payable, respectively. For the three and nine months ended September 30, 2024, two suppliers represented 45% and 49% of purchases, respectively. For the three and nine months ended September 30, 2023, one supplier represented 29% and two suppliers represented 40% of purchases, respectively. The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations. Investments

The Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary, including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss. Inventory

Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first-in, first-out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred. Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets. ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Debt Issuance Costs

Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023. Fair Value Option

Fair Value Options are permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments (ASC 825). The Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred. The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives. Revenue Recognition

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States. Product Net Sales

FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies (SPs) and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Sales Discounts

Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Company's sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized. Rebates

Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Company's estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Co-Payment Assistance

The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Company's estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period. Product Returns

Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. Research and Development Costs

Research and Development Costs Research and Development Costs Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead. Income Taxes

The Company accounts for income taxes in accordance with the FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals. As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Company's fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years. X - References

No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: stringItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + References Reference 1:

1:

observability of significant inputs) by class of liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] A Schedule of Fair Value of Debt Balance The following table presents the fair value of the Company's debt balance as of September 30, 2024 (in thousands): A A September 30, 2024 A Par value of the term loan A \$ 50,000 A Initial fair value adjustment A (1,855) A Fair value of the term loan at issuance A 48,145 A Change in fair value of the term loan A 2,954 A Total fair value of the term loan A \$ 51,099 A Schedule of Carrying Value of Debt Balance The following table presents the carrying value of the Company's debt balance as of December 31, 2023 (in thousands): A A December 31, 2023 A Face value A \$ 50,000 A Discount A (11,189) A Total A \$ 38,811 A Less: current portion A A – A Long-term portion A \$ 38,811 A X - DefinitionFair value of debt balance. + ReferencesNo definition available. + Details Name: scph FairValueOfDebtBalanceTableTextBlock Namespace Prefix: scph Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Estimated Fair Value of Options Valuation Assumptions The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions: A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A Risk-free interest rate A 3.40% - 4.23% A A 3.66% - 4.59% A Expected dividend yield A 0% A A 0% A Expected life A 5.5-6.98A years A A 5.5-6.7A years A Expected volatility A 77%-85% A A 76%-79% A Weighted-average grant date fair value A \$ 5.36 A A \$ 3.81 A Summary of Information about Stock Option Activity The following table summarizes information about stock option activity during the nine months ended September 30, 2024 (in thousands, except share and per share data): A A NUMBER OFSHARES A A WEIGHTED-AVERAGEEXERCISEPRICE A A WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM A A AGGREGATE INTRINSIC VALUE A Outstanding, December 31, 2023 A 4,681,326 A A 6.09 A A A A A A Granted A A 1,119,772 A A A 5.43 A A A A A Exercised A A (30,203) A A 2.85 A A A A A A Forfeited A A (325,420) A A 6.46 A A A A A Outstanding, September 30, 2024 A 5,445,475 A A A 5.95 A A A 6.81 A A A \$ 725 A Vested and exercisable, September 30, 2024 A 3,517,499 A A 6.15 A A A 5.76 A A A \$ 606 A Vested and expected to vest, September 30, 2024 A 5,081,614 A A 5.98 A A A 6.66 A A A \$ 709 A Schedule of RSU Activity The following table summarizes information about RSU activity during the nine months ended September 30, 2024: A A RSUs A A AVERAGE GRANTDATE FAIRVALUE (IN DOLLARS PER SHARE) A RSUs outstanding, December 31, 2023 A 368,411 A A 6.33 A A A 471,790 A A 5.70 A A Released A A (82,818) A A 6.33 A A A Forfeited A A (35,617) A A 6.24 A RSUs outstanding at September 30, 2024 A 721,766 A A 5.93 A Summary of Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2024 (in thousands): A A Three Months EndedSeptember 30, A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A A 2023 A A 2024 A Research and development A \$ 370 A A \$ 385 A A \$ 1,075 A A \$ 1,160 A General and administrative A 911 A A A 842 A A A 2,365 A A A 2,997 A Total A \$ 1,281 A A \$ 1,227 A A \$ 3,440 A A \$ 4,157 A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(f\)\(2\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2024 (in thousands): A Year ended: A A December 31, 2024 A \$ 96 A A December 31, 2025 A A 381 A A December 31, 2026 A A 376 A A December 31, 2027 A A 358 A A December 31, 2028 A A 367 A A Thereafter A A 249 A Total minimum lease payments A A 1,827 A Less imputed interest A A (429) A Total A \$ 1,398 A Schedule of Lease Cost and Other Information of Operating Lease Liabilities A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A Lease cost: A A A A Operating lease cost A \$ 497 A A \$ 261 A Short-term lease cost A 28 A A A 35 A Total lease cost A \$ 525 A A \$ 296 A Other information A A A A A Cash paid for amounts included in the measurement of lease liabilities A \$ 489 A A \$ 258 A Operating cash flows from operating leases A 8 A A \$ 10 A Weighted-average remaining lease term - operating leases A 5.5A years A A 4.8A years A Weighted-average discount rate - operating leases A A 11.6% A A 12.1% X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation - Additional Information (Details) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended Aug. 09, 2024 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Aug. 13, 2024 Dec. 31, 2023 Description Of Business And Basis Of Presentation [Line Items] A A A A Accumulated deficit A A \$ (347,649) A A (281,346) Cash and cash equivalents A A \$ 91,484 A A \$ 46,814 Aggregate offering price A A A \$ 53,500 A Common stock, par value A A \$ 0.0001 A A \$ 0.0001 Common Stock A A A A Description Of Business And Basis Of Presentation [Line Items] A A A A A Number of shares sold A 33,333 1,511 157 A A A Credit Agreement A A A A Description Of Business And Basis Of Presentation [Line Items] A A A A A Cash and cash equivalents \$ 5,000 A A A A Revenue Purchase and Sale Agreement A A A A A Description Of Business And Basis Of Presentation [Line Items] A A A A A Purchase price \$ 50,000 A A A A X - DefinitionAggregate offering price. + ReferencesNo definition available. + Details Name: scph AggregateOfferingPrice Namespace Prefix: scph Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDescription of business and basis of presentation. + ReferencesNo definition available. + Details Name: scph DescriptionOfBusinessAndBasisOfPresentationLineItems Namespace Prefix: scph Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPurchase price. + ReferencesNo definition available. + Details Name: scph PurchasePrice Namespace Prefix: scph Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-29](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-29) + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-30](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-30)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-50-11)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-50-17)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-30-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-30-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-28](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-28)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-29](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-29)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-9](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-9)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-50-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-30-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-30-1) + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=scph CreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=scph RevenuePurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT

v3.24.3 Significant Accounting Policies - Additional Information (Details) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD (\$) Supplier Customer Sep. 30, 2023 Supplier Customer Sep. 30, 2024 USD (\$) Supplier Customer Sep. 30, 2023 Supplier Customer Sep. 30, 2023 Supplier Customer Dec. 31, 2023 Customer Supplier Schedule Of Accounting Policies [Line Items] A A A A Potential interest and penalties associated with uncertain tax positions, accruals | \$ 0 A \$ 0 A A Amortized period for expenses incurred for research and development in united states A A 5 years A A Amortized period for expenses incurred for research and development outside united states A A 15 years A A Accounts Receivable A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Customer | Customer A A 2 A 3 Revenue A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Customer | Customer 2 2 3 1 A Accounts Payable A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Suppliers | Supplier A A 3 A 1 Purchases A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Suppliers | Supplier 2 1 2 2 A Customer Concentration Risk | Accounts Receivable | Customer Three A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A 99.00% Customer Concentration Risk | Accounts Receivable | Customer Two A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A 98.00% A A Customer Concentration Risk | Revenue | Customer Two A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk 98.00% 92.00% 99.00% A A Customer Concentration Risk | Revenue | Customer One A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A 88.00% A A Supplier Concentration Risk | Accounts Payable | Supplier One A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A 47.00% Supplier Concentration Risk | Accounts Payable | Supplier Three A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A 49.00% A A Supplier Concentration Risk | Purchases | Supplier One A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A 29.00% A A Supplier Concentration Risk | Purchases | Supplier Two A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk 45.00% A 49.00% 40.00% A X - Definition Amortized period for expenses incurred for research and development in united states. + ReferencesNo definition available. + Details Name: scph_AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates Namespace Prefix: scph_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Amortized period for expenses incurred for research and development outside united states. + ReferencesNo definition available. + Details Name: scph_AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates Namespace Prefix: scph_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Definition Number of customer. + ReferencesNo definition available. + Details Name: scph_NumberOfCustomer Namespace Prefix: scph_Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - Definition Number of suppliers. + ReferencesNo definition available. + Details Name: scph_NumberOfSuppliers Namespace Prefix: scph_Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - Definition Schedule of accounting policies. + ReferencesNo definition available. + Details Name: scph_ScheduleOfAccountingPoliciesLineItems Namespace Prefix: scph_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1:

valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1:

gaap_Data Type: dtr-types:percentItemBalance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemBalance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmNDfnHmNs' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Information about Stock Option Activity (Details) \$ / shares in Units, \$ in Thousands 9 Months Ended Dec. 29, 2023 Shares Sep. 30, 2024 USD (\$) / shares shares NUMBER OF SHARES A A Number of shares outstanding, beginning balance | shares A 4,681,326 Number of shares granted | shares A 1,119,772 Number of shares exercised | shares (24,343) (30,203) Number of shares forfeited | shares A (325,420) Number of shares outstanding, ending balance | shares A 5,445,475 Vested and exercisable, ending balance | shares A 3,517,499 Vested and expected to vest, ending balance | shares A 5,081,614 WEIGHTED-AVERAGE EXERCISE PRICE A A Weighted average exercise prices, outstanding beginning balance | \$ / shares A 6.09 Weighted average exercise prices, granted | \$ / shares A 5.43 Weighted average exercise prices, exercised | \$ / shares A 2.85 Weighted average exercise prices, forfeited | \$ / shares A 6.46 Weighted average exercise prices, outstanding ending balance | \$ / shares A 5.95 Weighted average exercise prices, vested and exercisable ending balance | \$ / shares A 6.15 Weighted average exercise prices, vested and expected to vest ending balance | \$ / shares A 5.98 WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM A A Weighted average remaining contractual term, outstanding A 6 years 9 months 21 days Weighted average remaining contractual term, vested and exercisable A 5 years 9 months 3 days Weighted average remaining contractual term, vested and expected to vest A 6 years 7 months 28 days AGGREGATE INTRINSIC VALUE A A Aggregate intrinsic value, outstanding ending balance | \$ A 725 Aggregate intrinsic value, vested and exercisable ending balance | \$ A 606 Aggregate intrinsic value, vested and expected to vest ending balance | \$ A 709 X - DefinitionShare based compensation arrangement by share based payment award options weighted average remaining contractual term. + ReferencesNo definition available. + Details Name: scph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract Namespace Prefix: scph_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(vii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(viii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(viii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(x\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(x) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xiii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xiii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xiv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xiv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xvi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xvi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xvii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xvii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xviii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xviii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(xix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 1](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(xx) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1:

... "auth_ref": [], "seph AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AggregateOfferingPrice", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price." }, "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } }, "auth_ref": ["ced AggtChngPnsnValnSummryCompstnTblForApblyrMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AggtChngPnsnValnSummryCompstnTblForApblyrMember", "presentation": ["http://xbrl.sec.gov/ced/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r784"], "ced AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ced/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r710", "r720", "r730", "r762"], "ced AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ced/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r713", "r723", "r733", "r765"], "ced AggtPnsnAdjsSvcsCstMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AggtPnsnAdjsSvcsCstMmber", "presentation": ["http://xbrl.sec.gov/ced/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r785"], "ced AllAdjToCompMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AllAdjToCompMmber", "presentation": ["http://xbrl.sec.gov/ced/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r751"], "ced AllExecutiveCategoriesMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AllExecutiveCategoriesMmber", "presentation": ["http://xbrl.sec.gov/ced/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r750"], "ced AllIndividualsMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AllIndividualsMmber", "presentation": ["http://xbrl.sec.gov/ced/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ced/role/ErrCompDisclosure", "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ced/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r714", "r724", "r734", "r758", "r766", "r770", "r778"], "ced AllTradingArrangementsMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AllTradingArrangementsMmber", "presentation": ["http://xbrl.sec.gov/ced/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r776"], "us gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement Expense", "terseLabel": "Total stock based compensation expense", "documentation": "Amount of expense for award under share based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r382", "r387"], "seph AllowanceForExcessDamagedAndObsoleteInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AllowanceForExcessDamagedAndObsoleteInventory", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"], "lang": { "en-us": { "role": { "label": "Allowance for excess, damaged and obsolete inventory", "terseLabel": "Allowance for excess, damaged and obsolete inventory" } } }, "auth_ref": ["del AmendmentFlag", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": ["us-gaap AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r5", "r77", "r316", "r894"], "seph AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates": { "xbrltype": "durationItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Amortized period for expenses incurred for research and development in united states", "terseLabel": "Amortized period for expenses incurred for research and development in united states" } } }, "auth_ref": ["seph AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates": { "xbrltype": "durationItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Amortized period for expenses incurred for research and development outside united states", "terseLabel": "Amortized period for expenses incurred for research and development outside united states" } } }, "auth_ref": ["us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from calculation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r198"], "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r25"], "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["us-gaap AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r25"], "us-gaap ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } }, "auth_ref": ["r407"], "us-gaap Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit" } } }, "auth_ref": ["r106", "r118", "r140", "r172", "r202", "r204", "r211", "r212", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r409", "r413", "r452", "r524", "r587", "r651", "r652", "r685", "r701", "r841", "r842", "r899"], "us-gaap AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": ["us-gaap AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "label": "Assets Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r134", "r148", "r172", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r409", "r413", "r452", "r685", "r841", "r842", "r898"], "us-gaap AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": ["us-gaap AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure", "totalLabel": "Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r427", "r428", "r673"], "us-gaap AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": ["seph AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "documentation": "At the market offering", "label": "At The Market Offering [Member]", "terseLabel": "At The Market Offering" } } }, "auth_ref": ["us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Accumulated Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r223"], "us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Accumulated Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r224"], "us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities Available for Sale, Amortized Cost", "totalLabel": "Cost Basis", "verboseLabel": "Amortized Cost Total", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r220", "r258", "r523"], "us-gaap AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Accumulated Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r221", "r258", "r427", "r517", "r673", "r676", "r826", "r878", "r879", "r880"], "ced AwardExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AwardExercisePrice", "presentation": ["http://xbrl.sec.gov/ced/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r773"], "ced AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ced/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r774"]

"},"ecadAwardTmgDiscLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgDiscLineItems","lang":{"en-us":{"role":{"label":"Award Timing Disclosures [Line Items]","terseLabel":"Award Timing Disclosures"}}}},"auth_ref":{"r769"},"ecadAwardTmgHowMnpiCnsdrdTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgHowMnpiCnsdrdTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Timing How MNPI Considered [Text Block]","terseLabel":"Award Timing How MNPI Considered"}}}},"auth_ref":{"r769"},"ecadAwardTmgMethodTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMethodTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Timing Method [Text Block]","terseLabel":"Award Timing Method"}}}},"auth_ref":{"r769"},"ecadAwardTmgMnpiCnsdrdFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiCnsdrdFlag","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Timing MNPI Considered [Flag]","terseLabel":"Award Timing MNPI Considered"}}}},"auth_ref":{"r769"},"ecadAwardTmgMnpiDiscTable":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiDiscTable","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Timing MNPI Disclosure [Table]","terseLabel":"Award Timing MNPI Disclosure"}}}},"auth_ref":{"r769"},"ecadAwardTmgPredtrmndFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgPredtrmndFlag","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Timing Predetermined [Flag]","terseLabel":"Award Timing Predetermined"}}}},"auth_ref":{"r769"},"us_gaap_AwardTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AwardTypeAxis","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Award Type [Axis]","terseLabel":"Award Type","documentation":{"Information by type of award under share-based payment arrangement."}}}}},"auth_ref":{"r356","r357","r358","r359","r360","r361","r362","r363","r364","r365","r366","r367","r368","r369","r370","r371","r372","r373","r374","r375","r376","r377","r378","r379","r380","r381"},"ecadAwardUnderlygSecuritiesAmt":{"xbrltype":"decimalItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardUnderlygSecuritiesAmt","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Award Underlying Securities Amount","terseLabel":"Underlying Securities"}}}},"auth_ref":{"r772"},"ecadAwardsCloseToMnpiDiscIndName":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscIndName","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Awards Close in Time to MNPI Disclosures, Individual Name","terseLabel":"Name"}}}},"auth_ref":{"r771"},"ecadAwardsCloseToMnpiDiscTable":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTable","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Awards Close in Time to MNPI Disclosures [Table]","terseLabel":"Awards Close in Time to MNPI Disclosures"}}}},"auth_ref":{"r770"},"ecadAwardsCloseToMnpiDiscTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTableTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"label":"Awards Close in Time to MNPI Disclosures [Table Text Block]","terseLabel":"Awards Close in Time to MNPI Disclosures, Table"}}}},"auth_ref":{"r770"},"seph_BorrowingsOneMember":{"xbrltype":"domainItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"BorrowingsOneMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Funded Immediately","label":"Borrowings One [Member]","documentation":{"Borrowings one."}}}}},"auth_ref":{"r770"},"seph_BorrowingsThreeMember":{"xbrltype":"domainItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"BorrowingsThreeMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"On or Prior to December 31, 2024","label":"Borrowings Three [Member]","documentation":{"Borrowings three."}}}}},"auth_ref":{"r770"},"seph_BorrowingsTwoMember":{"xbrltype":"domainItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"BorrowingsTwoMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Up to Two Draws on or Prior to September 30, 2024","label":"Borrowings Two [Member]","documentation":{"Borrowings two."},"verboselabel":"Up to Two Draws on or Prior to March 31, 2026"}}}}},"auth_ref":{"r770"},"us_gaap_BusinessDescriptionAndBasisOfPresentationTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessDescriptionAndBasisOfPresentationTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation"},"lang":{"en-us":{"role":{"label":"Business Description and Basis of Presentation [Text Block]","terseLabel":"Description of Business and Basis of Presentation","documentation":{"The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."}}}}}},"auth_ref":{"r53","r85","r86"},"us_gaap_BusinessExitCosts1":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessExitCosts1","erdr":"debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Exit fee","label":"Business Exit Costs","documentation":{"Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."}}}}},"auth_ref":{"r5"},"us_gaap_CashAndCashEquivalentsAtCarryingValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsAtCarryingValue","erdr":"debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Cash and Cash Equivalents at Carrying Value","terseLabel":"Cash and cash equivalents","verboselabel":"Cash and cash equivalents","totalLabel":"Cash and Cash Equivalents at Carrying Value, Total","periodStartLabel":"Cash and Cash Equivalents at Carrying Value, Beginning Balance","periodEndLabel":"Cash and Cash Equivalents at Carrying Value, Ending Balance","documentation":{"Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."}}}}},"auth_ref":{"r23","r137","r638"},"us_gaap_CashAndCashEquivalentsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsFairValueDisclosure","erdr":"debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"},"lang":{"en-us":{"role":{"label":"Cash and Cash Equivalents, Fair Value Disclosure","terseLabel":"Cash Instruments","documentation":{"Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}}}},"auth_ref":{"r876","r877"},"us_gaap_CashAndCashEquivalentsPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsPolicyTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"},"lang":{"en-us":{"role":{"terseLabel":"Cash and Cash Equivalents","label":"Cash and Cash Equivalents, Policy [Policy Text Block]","documentation":{"Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."}}}}},"auth_ref":{"r24"},"us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","erdr":"debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"},"lang":{"en-us":{"role":{"label":"Cash and cash equivalents at end of period","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents","totalLabel":"Cash, cash equivalents and restricted cash","periodStartLabel":"Cash and cash equivalents at beginning of period","documentation":{"Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}}}},"auth_ref":{"r23","r82","r168"},"us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","erdr":"debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"},"lang":{"en-us":{"role":{"label":"Net (decrease) increase in cash and cash equivalents","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect","documentation":{"Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}}}},"auth_ref":{"r0","r82"},"seph_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities","erdr":"credit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails"},"lang":{"en-us":{"role":{"documentation":{"Cash paid for amounts included in measurement of lease liabilities."},"label":"Cash Paid For Amounts Included In Measurement Of Lease Liabilities","terseLabel":"Cash paid for amounts included in the measurement of lease liabilities"}}}},"auth_ref":{"r0"},"seph_ChangeInFairValueOfTermLoan":{"xbrltype":"monetaryItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"ChangeInFairValueOfTermLoan","erdr":"credit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails"},"lang":{"en-us":{"role":{"terseLabel":"Change in fair value of the term loan","label":"Change in fair value of term loan","documentation":{"Change in fair value of term loan."}}}}},"auth_ref":{"r0"},"ecad_ChangedPeerGroupFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChangedPeerGroupFnTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Changed Peer Group, Footnote [Text Block]","terseLabel":"Changed Peer Group, Footnote"}}}},"auth_ref":{"r749"},"ecad_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]","terseLabel":"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"}}}},"auth_ref":{"r746"},"ecad_ChngInFrValOfOutstgAndUnvstdEqtyAwrdsGrntdInPrYrYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChngInFrValOfOutstgAndUnvstdEqtyAwrdsGrntdInPrYrYrMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]","terseLabel":"Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"}}}},"auth_ref":{"r744"},"dei_CityAreaCode":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"CityAreaCode","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentInformationAndEntityInformation"},"lang":{"en-us":{"role":{"label":"City Area Code","terseLabel":"City Area Code","documentation":{"Area code of city"}}}}}},"auth_ref":{"r0"},"us_gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1":{"xbrltype":"perShareItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Class of Warrant or Right, Exercise Price of Warrants or Rights","terseLabel":"Exercise price per share","documentation":{"Exercise price per share or per unit of warrants or rights outstanding."}}}}},"auth_ref":{"r339"},"us_gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Class of Warrant or Right, Number of Securities Called by Warrants or Rights","terseLabel":"Warrants to purchase of shares","documentation":{"Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."}}}}},"auth_ref":{"r339"},"us_gaap_ClassOfWarrantOrRightOutstanding":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightOutstanding","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Class of Warrant or Right, Outstanding","terseLabel":"Prefunded warrant shares","documentation":{"Number of warrants or rights outstanding."}}}}},"auth_ref":{"r0"},"ecad_CoSelectedMeasureAmt":{"xbrltype":"decimalItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CoSelectedMeasureAmt","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Company Selected Measure Amount","terseLabel":"Company Selected Measure Amount"}}}},"auth_ref":{"r750"},"ecad_CoSelectedMeasureName":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CoSelectedMeasureName","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Company Selected Measure Name","terseLabel":"Company Selected Measure Name"}}}},"auth_ref":{"r750"/>

"scph_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageAfterYearThree": { "xbrlType": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageAfterYearThree", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage after year three." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage After Year Three", "terseLabel": "Yield Protection Premium Percentage After Year Three" } } }, "auth_ref": [] }, "scph_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearOne": { "xbrlType": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearOne", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year one." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year One", "terseLabel": "Yield Protection Premium Percentage Year One" } } }, "auth_ref": [] }, "scph_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearThree": { "xbrlType": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearThree", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year three." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Three", "terseLabel": "Yield Protection Premium Percentage Year Three" } } }, "auth_ref": [] }, "scph_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearTwo": { "xbrlType": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearTwo", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year two." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Two", "terseLabel": "Yield Protection Premium Percentage Year Two" } } }, "auth_ref": [] }, "us_gaap_DebtPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DebtPolicyTextBlock", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "documentation": "Debt Policy [Policy Text Block]", "terseLabel": "Debt Issuance Costs", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r7"] }, "scph_DepositsAndOtherAssetsCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DepositsAndOtherAssetsCurrent", "order": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "documentation": "Deposits and other assets current.", "label": "Deposits And Other Assets Current", "terseLabel": "Deposits and other current assets" } } }, "auth_ref": [] }, "scph_DepositsAndOtherAssetsNoncurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DepositsAndOtherAssetsNoncurrent", "order": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "documentation": "Deposits and other assets noncurrent.", "label": "Deposits And Other Assets Noncurrent", "terseLabel": "Deposits and other assets", "verboselabel": "Deposits and other current assets" } } }, "auth_ref": [] }, "us_gaap_Depreciation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "Depreciation", "order": "debit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited", "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation Total", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r31"] }, "us_gaap_DerivativeContractTypeDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DerivativeContractTypeDomain", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r564", "r566", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r601", "r602", "r603", "r604", "r607", "r608", "r609", "r610", "r624", "r625", "r626", "r627", "r691", "r693", "r881", "r882", "r883", "r884", "r885", "r886", "r888", "r889"] }, "us_gaap_DerivativeInstrumentRiskAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r43", "r44", "r45", "r105", "r564", "r566", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r601", "r602", "r603", "r604", "r607", "r608", "r609", "r610", "r624", "r625", "r626", "r627", "r691", "r693", "r881", "r882", "r883", "r884", "r885", "r886", "r888", "r889"] }, "us_gaap_DerivativeLiabilitiesNoncurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DerivativeLiabilitiesNoncurrent", "order": "credit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Derivative Liability Noncurrent", "terseLabel": "Derivative liability", "documentation": "Fair value after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r140"] }, "us_gaap_DerivativeLiabilityMeasurementInput": { "xbrlType": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DerivativeLiabilityMeasurementInput", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "lang": { "en-us": { "role": { "verboselabel": "Measurement input", "label": "Derivative Liability Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": ["r420", "r430", "r431"] }, "scph_DerivativeLiabilityMember": { "xbrlType": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DerivativeLiabilityMember", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Derivative Liability", "label": "Derivative Liability [Member]", "documentation": "Derivative Liability" } } }, "auth_ref": [] }, "scph_DescriptionOfBusinessAndBasisOfPresentationLineItems": { "xbrlType": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localName": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Description of business and basis of presentation." } } }, "auth_ref": [] }, "us_gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Text Block]", "terseLabel": "Stock Based Compensation", "documentation": "The entire disclosure for share based payment arrangement." } } }, "auth_ref": ["r351", "r355", "r383", "r384", "r386", "r667"] }, "us_gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentDomain", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrlType": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentFiscalPeriodFocus", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY_Q1_Q2, and Q3_1st_2nd and 3rd quarter 10 Q or 10 QT statements have value Q1_Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrlType": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentFiscalYearFocus", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "verboselabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentInformationDocumentAxis", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentInformationLineItems", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentInformationTable", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentPeriodEndDate", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentQuarterlyReport", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r705"] }, "dei_DocumentTransitionReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentTransitionReport", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r737"] }, "dei_DocumentType": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localName": "DocumentType", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "eod_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrWrsRflctdInThCompForCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localName": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrWrsRflctdInThCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/eod/2024/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r748"] }, "us_gaap_EarningsPerShareAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us_gaap_EarningsPerShareBasic": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "EarningsPerShareBasic", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "verboselabel": "Net loss per share - basic", "terseLabel": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r161", "r181", "r182", "r183", "r184", "r185", "r186", "r193", "r195", "r196", "r197", "r201", "r403", "r406", "r424", "r425", "r510", "r539", "r648"] }, "us_gaap_EarningsPerShareDiluted": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "EarningsPerShareDiluted", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "verboselabel": "Net loss per share - diluted", "terseLabel": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r161", "r181", "r182", "r183", "r184", "r185", "r186", "r193", "r195", "r196", "r197", "r201", "r403", "r406", "r424", "r425", "r510", "r539", "r648"] }, "us_gaap_EarningsPerShareTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "EarningsPerShareTextBlock", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShare", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r190", "r198", "r199", "r200"] }, "us_gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "order": "credit", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair" } } }] }

Value of Embedded Derivative Liability", "terseLabel": "Fair value of embedded derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } , "auth_ref": { "r104", "r878", "r879", "r880" } } , "seph_EmbeddedDerivativeLiabilityUponIssuanceOfTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Embedded derivative liability upon issuance of Term Loan", "label": "Embedded derivative liability upon issuance of Term Loan" } } } , "auth_ref": { "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and related costs", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } , "auth_ref": { "r56" } } } , "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognition period (in years)", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } , "auth_ref": { "r385" } } } , "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } } , "auth_ref": { "r872" } } } , "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } , "auth_ref": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } } , "auth_ref": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } } , "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } } , "auth_ref": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } } , "auth_ref": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } } , "auth_ref": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } , "auth_ref": { "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } , "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports) and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } , "auth_ref": { "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } } , "auth_ref": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } , "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two character EDGAR code representing the state or country of incorporation." } } } , "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } , "auth_ref": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } , "auth_ref": { "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } , "auth_ref": { "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } , "auth_ref": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } } , "auth_ref": { "ced_EqtyAwrdsAdjFnTxBk": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTxBk", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote", "documentation": "Footnote" } } } , "auth_ref": { "ced_EqtyAwrdsAdjExclValRprtInSummryCompstnTblMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclValRprtInSummryCompstnTblMmber", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "documentation": "Footnote" } } } , "auth_ref": { "ced_EqtyAwrdsAdjMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMmber", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments", "documentation": "Footnote" } } } , "auth_ref": { "ced_EqtyAwrdsInSummryCompstnTblForApblYrMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMmber", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "documentation": "Footnote" } } } , "auth_ref": { "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "documentation": "Footnote" } } } , "auth_ref": { "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } , "auth_ref": { "r109", "r132", "r157", "r158", "r159", "r176", "r177", "r178", "r180", "r185", "r187", "r189", "r203", "r251", "r252", "r268", "r340", "r398", "r399", "r400", "r401", "r402", "r404", "r405", "r406", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r453", "r454", "r455", "r456", "r457", "r458", "r463", "r464", "r478", "r535", "r545", "r546", "r547", "r562", "r613" } } , "ced_EqtyValuationAssumptionDifferenceFnTxBk": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyValuationAssumptionDifferenceFnTxBk", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote", "documentation": "Footnote" } } } , "auth_ref": { "ced_ErrCompAnalysisTxBk": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTxBk", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis", "documentation": "Footnote" } } } , "auth_ref": { "r710", "r720", "r730", "r762" } } , "ced_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery", "documentation": "Footnote" } } } , "auth_ref": { "r707", "r717", "r727", "r759" } } , "ced_ExecuiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecuiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category", "documentation": "Footnote" } } } , "auth_ref": { "r759" } } } , "seph_FairValueAdjustmentToDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "Fair Value Adjustment To Derivative Liability" } } }

"FairValueAdjustmentToDerivativeLiability","order":"debit","presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited","lang":{"en-us":{"role":{"documentation":"Fair value adjustment to derivative liability"},"label":"Fair Value Adjustment To Derivative Liability","terseLabel":"Fair value adjustment to derivative liability"},"auth_ref":{"1"},"seph_FairValueAdjustmentToRevenuePurchaseAndSaleLiability":{"xbrlytpe":"monetaryItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"FairValueAdjustmentToRevenuePurchaseAndSaleLiability"},"order":"debit","presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited","lang":{"en-us":{"role":{"negatedLabel":"Change in fair value of revenue purchase and sale liability"},"label":"Fair Value Adjustment to Revenue Purchase and Sale Liability","documentation":"Fair value adjustment to revenue purchase and sale liability"},"auth_ref":{"1"},"seph_FairValueAdjustmentToTermLoan":{"xbrlytpe":"monetaryItemType","nsuri":"http://www.sepharmaceuticals.com/20240930","localname":"FairValueAdjustmentToTermLoan"},"order":"debit","presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited","lang":{"en-us":{"role":{"negatedLabel":"Change in fair value of term loan"},"label":"Fair Value Adjustment to Term Loan","documentation":"Fair value adjustment to term loan"},"auth_ref":{"1"},"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails","lang":{"en-us":{"role":{"label":"Fair Value, Recurring and Nonrecurring [Table]"},"documentation":"Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis"},"auth_ref":{"r427","r428","r441","r673"},"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails","lang":{"en-us":{"role":{"label":"Fair Value Measurement Inputs and Valuation Techniques [Table]"},"terseLabel":"Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"},"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table"},"auth_ref":{"r429","r430","r431","r676"},"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Fair Value Measurement Inputs and Valuation Techniques [Table]"},"terseLabel":"Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"},"documentation":"Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis"},"auth_ref":{"r429","r430","r431","r676"},"us_gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain":{"xbrlytpe":"domainItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Asset Class [Domain]"},"terseLabel":"Asset Class"},"documentation":"Class of asset"},"auth_ref":{"r432","r433","r434","r435","r436","r437","r442","r674"},"us_gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOffairValueOfDebtBalanceDetails","lang":{"en-us":{"role":{"label":"Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"},"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table"},"auth_ref":{"1"},"us_gaap_FairValueByAssetClassAxis":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueByAssetClassAxis"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Asset Class [Axis]"},"terseLabel":"Asset Class"},"documentation":"Information by class of asset"},"auth_ref":{"r432","r433","r434","r435","r436","r437","r442","r674"},"us_gaap_FairValueByBalanceSheetGroupingTable":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueByBalanceSheetGroupingTable"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOffairValueOfDebtBalanceDetails","lang":{"en-us":{"role":{"label":"Fair Value, Balance Sheet Grouping [Table]"},"documentation":"Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities"},"auth_ref":{"r46","r47"},"us_gaap_FairValueByFairValueHierarchyLevelAxis":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueByFairValueHierarchyLevelAxis"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Fair Value Hierarchy and NAV [Axis]"},"terseLabel":"Fair Value Hierarchy and NAV"},"documentation":"Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient"},"auth_ref":{"r308","r344","r345","r346","r347","r348","r349","r426","r428","r429","r430","r431","r440","r441","r442","r484","r485","r486","r656","r657","r662","r664","r665","r673"},"us_gaap_FairValueByMeasurementFrequencyAxis":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueByMeasurementFrequencyAxis"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Measurement Frequency [Axis]"},"terseLabel":"Measurement Frequency"},"documentation":"Information by measurement frequency"},"auth_ref":{"r427","r428","r429","r431","r673"},"us_gaap_FairValueDisclosuresAbstract":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueDisclosuresAbstract"},"lang":{"en-us":{"role":{"label":"Fair Value Disclosures [Abstract]"},"auth_ref":{"1"},"us_gaap_FairValueDisclosuresTextBlock":{"xbrlytpe":"textBlockItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueDisclosuresTextBlock"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Fair Value of Financial Instruments"},"documentation":"The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration; (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item; (c) policy for requiring collateral or other security and information as to accessing such collateral or security; and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election; (b) discussion of the effect of fair value changes on earnings; (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information"},"auth_ref":{"r436","r438","r439","r440","r443","r444","r445","r446","r447","r516","r673","r677"},"us_gaap_FairValueInputsLevel1Member":{"xbrlytpe":"domainItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueInputsLevel1Member"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Fair Value, Inputs, Level 1 [Member]"},"terseLabel":"Quoted Prices in Active Markets (Level 1) [Member]"},"documentation":"Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date"},"auth_ref":{"r308","r344","r349","r428","r441","r484","r662","r664","r665","r673"},"us_gaap_FairValueInputsLevel2Member":{"xbrlytpe":"domainItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueInputsLevel2Member"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Fair Value, Inputs, Level 2 [Member]"},"terseLabel":"Significant Other Observable Inputs (Level 2) [Member]"},"documentation":"Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets"},"auth_ref":{"r308","r344","r349","r428","r429","r441","r485","r656","r663","r664","r665","r673"},"us_gaap_FairValueInputsLevel3Member":{"xbrlytpe":"domainItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueInputsLevel3Member"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Fair Value, Inputs, Level 3 [Member]"},"terseLabel":"Significant Unobservable Inputs (Level 3) [Member]"},"documentation":"Significant Unobservable Inputs (Level 3) [Member]"},"documentation":"Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing"},"auth_ref":{"r308","r344","r345","r346","r347","r348","r349","r428","r429","r430","r431","r441","r486","r656","r657","r662","r664","r665","r673","r676"},"us_gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"},"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table"},"auth_ref":{"r432","r433","r434","r435","r436","r437","r442"},"us_gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock":{"xbrlytpe":"textBlockItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"},"documentation":"Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input"},"auth_ref":{"r432","r433","r434","r435","r436","r437","r442"},"us_gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable":{"xbrlytpe":"stringItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"},"presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails","lang":{"en-us":{"role":{"label":"Measurement Frequency [Domain]"},"terseLabel":"Measurement Frequency"},"documentation":"Measurement frequency"},"auth_ref":{"r427","r428","r429","r431","r673","r679","r690"},"us_gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings":{"xbrlytpe":"monetaryItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"},"order":"credit","presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Change in fair value"},"label":"Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings"},"terseLabel":"Change in fair value of derivative liability"},"documentation":"Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)"},"auth_ref":{"r433","r442"},"us_gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues":{"xbrlytpe":"monetaryItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"},"order":"credit","presentation":-1
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails","lang":{"en-us":{"role":{"label":"Initial fair value"},"label":"Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances"},"documentation":"Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing"},"auth_ref":{"r435","r442"},"us_gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue":{"xbrlytpe":"monetaryItemType","nsuri":"http://fasb.org/us_gaap/2024","localname":"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue"},"order":"credit","presentation":-1

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}], "lang": {"en-us": {"role": {"label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }}, {"auth_ref": {"r422": "r422", "r442": "r442"}, "us-gaap-FairValueMeasurementsFairValueHierarchyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}], "lang": {"en-us": {"role": {"label": "Fair Value Hierarchy and NAV [Domain]", "terselabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-FairValueMeasurementsRecurringMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"}], "lang": {"en-us": {"role": {"label": "Fair Value, Recurring [Member]", "terselabel": "Fair Value, Measurements, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." }}, {"auth_ref": {"r673": "r673", "r877": "r877", "r878": "r878", "r879": "r879", "r880": "r880", "r890": "r890"}}, {"seph-FairValueOfDebtBalanceTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfDebtBalanceTableTextBlock", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesTables"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Fair Value of Debt Balance", "label": "Fair value of Debt Balance [Table Text Block]", "documentation": "Fair value of debt balance." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-FairValueOfFinancialInstrumentsPolicy": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"}], "lang": {"en-us": {"role": {"label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." }}, {"auth_ref": {"r810": "r810"}, "seph-FairValueOfTermLoanAtIssuance": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfTermLoanAtIssuance", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails"}], "lang": {"en-us": {"role": {"label": "Fair value of the term loan at issuance", "label": "Fair value of term loan at issuance", "documentation": "Fair value of term loan at issuance." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-FairValueOfWarrantsIssued": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfWarrantsIssued", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Fair value of warrants issued", "label": "Fair value of warrants issued", "documentation": "Fair value of warrants issued." }}, {"auth_ref": {"r309": "r309", "r344": "r344"}, "us-gaap-FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {"xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails"}], "lang": {"en-us": {"role": {"label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."}}, {"auth_ref": {"r433": "r433", "r442": "r442"}, "us-gaap-FinancialInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Financial Instrument [Axis]", "terselabel": "Financial Instrument", "documentation": "Information by type of financial instrument." }}, {"auth_ref": {"r219": "r219", "r220": "r220", "r221": "r221", "r222": "r222", "r223": "r223", "r224": "r224", "r225": "r225", "r226": "r226", "r227": "r227", "r228": "r228", "r229": "r229", "r230": "r230", "r231": "r231", "r232": "r232", "r233": "r233", "r234": "r234", "r235": "r235", "r236": "r236", "r237": "r237", "r238": "r238", "r239": "r239", "r240": "r240", "r241": "r241", "r242": "r242", "r243": "r243", "r244": "r244", "r245": "r245", "r246": "r246", "r247": "r247", "r248": "r248", "r249": "r249", "r250": "r250", "r251": "r251", "r252": "r252", "r253": "r253", "r254": "r254", "r255": "r255", "r256": "r256", "r257": "r257", "r258": "r258", "r259": "r259", "r260": "r260", "r319": "r319", "r337": "r337", "r421": "r421", "r448": "r448", "r481": "r481", "r482": "r482", "r483": "r483", "r484": "r484", "r485": "r485", "r486": "r486", "r487": "r487", "r488": "r488", "r489": "r489", "r490": "r490", "r491": "r491", "r492": "r492", "r493": "r493", "r494": "r494", "r495": "r495", "r498": "r498", "r499": "r499", "r500": "r500", "r501": "r501", "r502": "r502", "r503": "r503", "r504": "r504", "r505": "r505", "r506": "r506", "r507": "r507", "r508": "r508", "r509": "r509", "r510": "r510", "r511": "r511", "r512": "r512", "r536": "r536", "r654": "r654", "r673": "r673", "r674": "r674", "r676": "r676", "r677": "r677", "r678": "r678", "r681": "r681", "r682": "r682", "r689": "r689", "r792": "r792", "r793": "r793", "r794": "r794", "r795": "r795", "r796": "r796", "r797": "r797", "r798": "r798", "r827": "r827", "r828": "r828", "r829": "r829", "r830": "r830", "r875": "r875", "r878": "r878", "r880": "r880", "r887": "r887", "r890": "r890"}}, {"ced-ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terselabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}}, {"ced-ForgoneRecoveryDueToExpenseOfEnforcementAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Forgone Recovery due to Expense of Enforcement, Amount", "terselabel": "Forgone Recovery due to Expense of Enforcement, Amount"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}}, {"ced-ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terselabel": "Forgone Recovery due to Violation of Home Country Law, Amount"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}}, {"ced-ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terselabel": "Forgone Recovery, Explanation of Impracticability"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}}, {"ced-ForgoneRecoveryIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryIndName", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"label": "Forgone Recovery, Individual Name", "terselabel": "Name"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}}, {"ced-FrValAsOfPrYrEndOfEqtyAwrdsGmtInPrYrsFldVstngCondsDrngCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGmtInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [{"url": "http://xbrl.sec.gov/ced/role/PvpDisclosure"}, {"url": "http://xbrl.sec.gov/ced/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terselabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"}}, {"auth_ref": {"r474": "r474"}, "us-gaap-FurnitureAndFixturesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails"}], "lang": {"en-us": {"role": {"label": "Furniture and Fixtures [Member]", "terselabel": "Office Furniture", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-GainsLossesOnExtinguishmentOfDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Loss on extinguishment of debt", "label": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." }}, {"auth_ref": {"r5": "r5", "r35": "r35", "r36": "r36"}, "us-gaap-GeneralAndAdministrativeExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}], "lang": {"en-us": {"role": {"label": "General and Administrative Expense [Member]", "terselabel": "General and Administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." }}, {"auth_ref": {"r76": "r76"}, "us-gaap-IncomeStatementAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {"en-us": {"role": {"label": "Income Statement [Abstract]"}}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-IncomeStatementLocationAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}], "lang": {"en-us": {"role": {"label": "Statement of Income Location, Balance [Axis]", "terselabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." }}, {"auth_ref": {"r269": "r269", "r275": "r275", "r276": "r276", "r433": "r433", "r437": "r437", "r442": "r442", "r542": "r542", "r544": "r544", "r598": "r598", "r635": "r635", "r675": "r675", "r911": "r911"}, "us-gaap-IncomeStatementLocationDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"}], "lang": {"en-us": {"role": {"label": "Statement of Income Location, Balance [Domain]", "terselabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." }}, {"auth_ref": {"r275": "r275", "r276": "r276", "r433": "r433", "r437": "r437", "r442": "r442", "r542": "r542", "r544": "r544", "r598": "r598", "r635": "r635", "r675": "r675", "r911": "r911"}, "us-gaap-IncomeTaxPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"}], "lang": {"en-us": {"role": {"label": "Income Tax, Policy [Policy Text Block]", "terselabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." }}, {"auth_ref": {"r156": "r156", "r391": "r391", "r392": "r392", "r394": "r394", "r395": "r395", "r396": "r396", "r397": "r397", "r557": "r557"}, "us-gaap-IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "cred": "debit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terselabel": "Accounts payable, accrued expenses and other liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." }}, {"auth_ref": {"r4": "r4"}, "us-gaap-IncreaseDecreaseInAccountsReceivable": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Increase (Decrease) in Accounts Receivable", "label": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." }}, {"auth_ref": {"r4": "r4"}, "us-gaap-IncreaseDecreaseInInventories": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." }}, {"auth_ref": {"r4": "r4"}, "us-gaap-IncreaseDecreaseInOperatingCapitalAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Increase (Decrease) in Operating Capital [Abstract]", "terselabel": "Changes in operating assets and liabilities"}}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "seph-IncreaseDecreaseInOperatingLeasePayments": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "IncreaseDecreaseInOperatingLeasePayments", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails"}], "lang": {"en-us": {"role": {"label": "documentation": "Increase decrease in operating lease payments.", "label": "Increase Decrease In Operating Lease Payments", "verboseLabel": "Operating cash flows from operating leases"}}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Increase (Decrease) in Prepaid Expense and Other Assets", "label": "Prepaid expenses and other assets", "documentation": "The increase (decrease) in Prepaid Expense and Other Assets, Total." }}, {"auth_ref": {"r4": "r4"}, "us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "cred": "credit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"}], "lang": {"en-us": {"role": {"label": "Initial Draw Amount", "cred": "debit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Initial Draw Amount", "label": "Initial Draw Amount", "documentation": "Initial draw amount." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "ced-InsiderTradingArrLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingArrLineItems", "lang": {"en-us": {"role": {"label": "Insider Trading Arr Line Items", "label": "Insider Trading Arr Line Items", "documentation": "Insider Trading Arr Line Items." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}, "us-gaap-InitialDrawAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "InitialDrawAmount", "cred": "debit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Initial Draw Amount", "label": "Initial Draw Amount", "documentation": "Initial draw amount." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "ced-InsiderTradingArrLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingArrLineItems", "lang": {"en-us": {"role": {"label": "Insider Trading Arr Line Items", "label": "Insider Trading Arr Line Items", "documentation": "Insider Trading Arr Line Items." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}}, {"auth_ref": {"r714": "r714", "r724": "r724", "r734": "r734", "r766": "r766"}, "us-gaap-InitialDrawAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "InitialDrawAmount", "cred": "debit", "presentation": [{"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"url": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Initial Draw Amount", "label": "Initial Draw Amount", "documentation": "Initial draw amount." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r440": "r440", "r441": "r441", "r442": "r442", "r484": "r484", "r485": "r485", "r656": "r656", "r657": "r657", "r663": "r663", "r664": "r664", "r665": "r665", "r673": "r673", "r676": "r676"}, "ced-InsiderTradingArrLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingArrLineItems", "lang": {"en-us": {"role": {"label": "Insider Trading Arr Line Items", "label": "Insider Trading Arr Line Items", "documentation": "Insider Trading Arr Line Items." }}, {"auth_ref": {"r309": "r309", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r426": "r426", "r428": "r42

... "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": { "r897" } }, "us_gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "Future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r475" } }, "seph_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": { "us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r475" } }, "us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r475" } }, "us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r475" } }, "us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r475" } }, "us_gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "terseLabel": "December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r897" } }, "us_gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiab", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r475" } }, "us_gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Letter Of Credit Member", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": { "us_gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r15", "r55", "r56", "r57", "r59", "r60", "r61", "r62", "r172", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r410", "r413", "r414", "r452", "r573", "r649", "r704", "r841", "r898", "r899" } }, "us_gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders'2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r69", "r110", "r530", "r685", "r811", "r831", "r891" } }, "us_gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders'2019 Equity" } } }, "auth_ref": { "us_gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r57", "r135", "r172", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r410", "r413", "r414", "r452", "r685", "r841", "r898", "r899" } }, "us_gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "auth_ref": { "us_gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "label": "Initial fair value adjustment", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": { "us_gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesScheduleOfFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "lang": { "en-us": { "role": { "totalLabel": "Liabilities, Fair Value Disclosure, Total", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": { "r428", "r876" } }, "us_gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesScheduleOfFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "seph_LondonInterbankOfferedRatesLiborMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LondonInterbankOfferedRatesLiborMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Libor", "label": "London Interbank Offered Rates LIBOR [Member]", "documentation": "London Interbank Offered Rates LIBOR [Member]" } } }, "auth_ref": { "seph_LongTermAdditionalDebtDiscountExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermAdditionalDebtDiscountExitFee", "credit": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term additional debt discount exit fee.", "label": "Long Term Additional Debt Discount Exit Fee", "terseLabel": "Long term additional debt discount exit fee" } } }, "auth_ref": { "us_gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "label": "Long Term Debt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long term debt. Excludes lease obligation." } } }, "auth_ref": { "r15", "r108", "r307", "r322", "r656", "r657", "r683", "r909" } }, "seph_LongTermDebtAmortizationOfFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtAmortizationOfFinalPaymentFee", "credit": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt amortization of final payment fee.", "label": "Long Term Debt Amortization Of Final Payment Fee", "terseLabel": "Amortization of final payment fee" } } }, "auth_ref": { "us_gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "label": "Long Term Debt, Current Maturities", "terseLabel": "Term loan, short-term", "negatedLabel": "Less: current portion", "totalLabel": "Long term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long term debt classified as current. Excludes lease obligation." } } }, "auth_ref": { "r141" } }, "seph_LongTermDebtExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtExitFee", "credit": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt exit fee.", "label": "Long Term Debt Exit Fee", "terseLabel": "Exit fee" } } }, "auth_ref": { "seph_LongTermDebtExitFeeObligationAccountedAsDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtExitFeeObligationAccountedAsDerivativeLiability", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt exit fee obligation accounted as derivative liability.", "label": "Long Term Debt Exit Fee Obligation Accounted As Derivative Liability", "terseLabel": "Derivative liability recorded against exit fee obligation" } } }, "auth_ref": { "seph_LongTermDebtExitFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtExitFeePercentage", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt exit fee percentage.", "label": "Long Term Debt Exit Fee Percentage", "terseLabel": "Exit fee, percentage" } } }, "auth_ref": { "seph_LongTermDebtFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtFinalPaymentFee", "credit": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt final payment fee.", "label": "Long Term Debt Final Payment Fee", "terseLabel": "Final payment fee" } } }, "auth_ref": { "seph_LongTermDebtIncrementOnInterestRateOnDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtIncrementOnInterestRateOnDefault", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt increment on interest rate on default.", "label": "Long Term Debt Increment On Interest Rate On Default", "terseLabel": "Increase in interest rate on default" } } }, "auth_ref": { "us_gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "credit": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "label": "Term loan", "totalLabel": "Carrying value of term loan", "verboseLabel": "Long term portion", "terseLabel": "Term loan, long term", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": { "r143" } }, "seph_LongTermDebtPrepaymentPremiumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumAmount", "credit": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Long term debt

"documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, released in period" } } , "auth_ref": [] } } , "seph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageReleasedFairValue": { "xbrltype": "perShareItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageReleasedFairValue", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "AVERAGE GRANT DATE FAIR VALUE, Released" } , "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other Than Options, Weighted Average Released Fair Value" } } , "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, weighted average released fair value" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Stock option and incentive plan expiration date" } , "label": "Share Based Compensation Arrangement by Share Based Payment Award, Expiration Date" } } , "documentation": "Date the equity based award expires, in YYYY-MM-DD format" } } , "auth_ref": ["r847"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Exercise Price" } , "terseLabel": "Exercise price per warrant" } } , "documentation": "Agreed upon price for the exchange of the underlying asset relating to the share based payment award" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } , "terseLabel": "Expected dividend yield" } } , "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term" } } , "auth_ref": ["r379"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } , "terseLabel": "Expected volatility" } } , "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period" } } , "auth_ref": ["r378"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum" } , "terseLabel": "Expected volatility, maximum" } } , "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum" } , "terseLabel": "Expected volatility, minimum" } } , "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureFinancialLiabilitiesAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } , "terseLabel": "Risk free rate" } } , "documentation": "The risk free interest rate assumption that is used in valuing an option on its own shares" } } , "auth_ref": ["r380"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum" } , "terseLabel": "Risk free interest rate, maximum" } } , "documentation": "The maximum risk free interest rate assumption that is used in valuing an option on its own shares" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum" } , "terseLabel": "Risk free interest rate, minimum" } } , "documentation": "The minimum risk free interest rate assumption that is used in valuing an option on its own shares" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Non Option Equity Instruments, Granted" } , "terseLabel": "Equity awards granted under the inducement , Granted" } } , "documentation": "Net number of non option equity instruments granted to participants" } } , "auth_ref": ["r11"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"] , "lang": { "en-us": { "role": { "periodStartLabel": "RSUs outstanding", "periodEndLabel": "RSUs outstanding" } , "label": "Share Based Compensation Arrangement by Share Based Payment Award, Non Option Equity Instruments, Outstanding Number" } } , "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments" } } , "auth_ref": ["r99", "r100"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Authorized" } , "terseLabel": "Number of common shares authorized for issuance" } } , "documentation": "Number of shares authorized for issuance under share based payment arrangement" } } , "auth_ref": ["r669"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Available for Grant" } , "terseLabel": "Stock options, available for issuance" } } , "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable" } } , "auth_ref": ["r39"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Additional Disclosures [Abstract]" } , "terseLabel": "AGGREGATE INTRINSIC VALUE" } } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable Number" } , "terseLabel": "Vested and exercisable, ending balance" } } , "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan" } } , "auth_ref": ["r361"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } , "terseLabel": "Weighted average exercise prices, vested and exercisable ending balance" } } , "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan" } } , "auth_ref": ["r361"] } } , "seph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeited": { "xbrltype": "sharesItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeited", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options forfeited" } , "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Forfeited" } } , "terseLabel": "Number of options forfeited" } } , "auth_ref": [] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Forfeitures in Period" } , "negatedLabel": "Number of shares forfeited" } } , "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan" } } , "auth_ref": ["r365"] } } , "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross", "presentation": ["http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Cross" } , "terseLabel": "Additional options granted" } } , "documentation": "Number of

amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Co-payment Assistance: The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Company's estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period.

Product Returns: Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry.

Research and Development Costs: Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead.

Income Taxes: Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized.

The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is "more likely than not" to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals.

Net Loss per Share: Net Loss per Share. Net Loss per Share is calculated as follows:

| Year | Net Loss per Share |
|------|--------------------|
| 2023 | 15.634 |
| 2024 | 15.634 |

The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data):

| Year | Net Loss | Weighted Average Shares | Net Loss per Share |
|------|----------|-------------------------|--------------------|
| 2023 | 15,634 | 1,000,000 | 15.634 |
| 2024 | 15,634 | 1,000,000 | 15.634 |

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></tr><tr style="height:10pt;background-color:#fffff0;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in fair value of the term loan</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.954</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff0;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ff00ff;word-break:break-word;"><td style="text-indent:1.5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total fair value of the term loan</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51,099</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff0;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Borrowings under the Term Loan bear interest at a rate per annum equal to the one-month term SOFR (subject to a3.25</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.75</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">payable</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">monthly</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">in arrears. There will be</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">scheduled repayments of outstanding principal on the Term Loan prior to</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">August 9, 2029</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">the "Maturity Date"). The Company may voluntarily prepay the outstanding Term Loan, subject to a yield protection premium equal to (i)</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">of the principal amount of the Term Loan prepaid, if prepaid on or prior to the first anniversary of the Closing Date, (ii)</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, (iii)</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date, with</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">prepayment premium due after the third anniversary of the Closing date through the Maturity Date.</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">On the Closing Date, the Company was required to issue to the Lenders of such Term Loan warrants to purchase300,000</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">of shares of the Company's common stock, in the aggregate (the</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Warrant"), at an exercise price of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5992</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">. Upon the completion of the sale of common stock on August 13, 2024 (Note 10), the exercise price of the warrants was adjusted to</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">according to the terms of the agreement. Upon inception, the Company evaluated the warrants and determined that they met all the requirements for equity classification under ASC Topic 815</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Derivatives and Hedging</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">("ASC 815"). This transaction was accounted for as a detachable warrant at its fair value, using the residual method, and is recorded as an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.33</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the exercise price per warrant equal to</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the expected volatility of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">87.5</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the risk-free interest rate</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">6</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">years and the absence of a dividend. The Warrant is immediately exercisable, and the exercise period will expire</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">6 years</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">from the date of issuance.</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">In addition to the Warrant, the Company will be required to issue to the Lenders warrants to purchase200,000</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">of shares of the Company's common stock (the "Tranche B Warrant") upon the draw down of the second tranche of the Term Loan on or prior to March 31, 2026. These warrants were accounted for using the residual method and were recorded on a relative fair value basis, resulting in an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.33</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the exercise price per warrant equal to</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">4.00</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the expected volatility of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">82.5</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the risk-free interest rate of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">3.875</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the contractual term of</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">6</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">years and the absence of a dividend. The Tranche B Warrant will expire</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">6 years</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">from the date of issuance.</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's obligations under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement) will be guaranteed by any domestic subsidiaries of ours that become Guarantors (as defined in the Credit Agreement), subject to certain exceptions. The Borrowers' and the Guarantors' (collectively, the</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Loan Parties"></p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">respective obligations under the Credit Agreement and the other Loan Documents are secured by first priority security interests in substantially all assets of the Loan Parties, subject to certain customary thresholds and exceptions.</p><p style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div>

